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Bone’s functional and geometric properties in dystrophin-deficient
mice and the efficacy of low intensity vibration training to improve
musculoskeletal function
by Susan Anne Novotny
ABSTRACT
Overall, my dissertation work has shown that bone health is affected in dystrophic
mice secondary to the muscle disease (Chapter 3), and both prednisolone and physical
inactivity accentuate these declines (Chapter 4). I identified two sets of low intensity,
high frequency vibration parameters (45 Hz at 0.6 g and 90 Hz at 0.6 g) that initi-
ated an osteogenic response in mdx mice. Further experiments were performed utilizing
the 45 Hz and 0.6 g setting, the results of which indicated that vibration was safe for
dystrophic muscle (Chapters 5 and 6). However, long-term training adaptations for
musculoskeletal function were not realized (Chapter 6). The lack of adaptations follow-
ing vibration training in mdx or wildtype mice does not negate the utility of vibration
as a potential therapeutic exercise modality for DMD, but further research, utilizing
alternative strategies, is needed to determine the full extent of vibrations capacity to
improve musculoskeletal health.
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Chapter 1
Introduction
1
2Duchenne muscular dystrophy (DMD) is a disease characterized by progressive mus-
cle weakness and physical inactivity, which reduces the frequency and magnitude of
mechanical loads placed on bone. Consequent to these reductions in mechanical load-
ing is the initiation of bone loss, which structurally weakens the bone and predisposes
it to fracture. Fracture incidence is on the rise in DMD patients and ranges between
18-44%, where higher incidence rates parallel increased age, physical limitations and
disease states [1, 2, 3]. Despite increased fracture incidence, few studies have charac-
terized skeletal health in DMD patients beyond bone mass [4, 5, 6], and at the time
of initiating this dissertation work, clinical interventions focused on identifying bone-
sparing modalities of exercise were not published. This is largely attributed to the
fact that DMD patients are advised to avoid osteogenic physical activities, due to the
potential that these high intensity activities may injure the inherently fragile muscle
tissue. Thus, the development of safe, yet effective, therapeutic modalities are war-
ranted to preserve bone health in DMD. The overall purpose of this dissertation was
therefore, to determine the safety and efficacy of low intensity, high frequency vibration
training to improve musculoskeletal health in a mouse model of DMD. The following
three specific aims were developed to address this issue. The first aim was to confirm
that bone health was compromised secondary to the muscle disease in mouse models
of DMD and to identify the underlying mechanisms. The second aim was to determine
the extent to which physical inactivity and prednisolone treatment (i.e., the glucocorti-
coid which is the gold-standard treatment to preserve muscle strength in DMD) further
impact dystrophic bone health. The final aim was to determine the safety and efficacy
of low intensity, high frequency vibration training as a potential therapeutic modality
to preserve, and potentially improve, dystrophic musculoskeletal health.
Chapter 2 provides contextual background necessary to understand the motivation
behind this dissertation work. This chapter reviews the relevant literature with regard
to the importance of mechanical loading on bone health, the role of muscle in mechanical
loading, the muscle disease DMD, the impact DMD has on bone health, and the use of
vibration as a potential therapy to improve musculoskeletal health.
Chapters 3-6 are written in manuscript form and represent the sequential aims of my
dissertation. Chapter 3 is a paper characterizing the extent to which tibial bone strength
was compromised in two mouse models of DMD (i.e., mdx and double-knockout (dko)
3mice) compared to healthy wildtype mice and what geometric and intrinsic material
properties of bone contributed to alterations in strength. Two studies had previously
investigated skeletal health in mdx mice; however, their findings were conflicting and
consequently it remained unknown if these mice had a skeletal phenotype similar to
boys with DMD [7, 8]. Therefore, the basis for this study was to characterize the
phenotype of young and aged mdx and dko mice. The results of this study confirmed
that dystrophic mice indeed have compromised bone strength, smaller cortical bone
geometry, and altered trabecular bone morphometry, making them useful models to
identify therapeutic regimens aimed at improving dystrophic skeletal health.
Chapter 4 discusses the findings of a study that examines the extent to which two
known catabolic factors of DMD, that is, prednisolone treatment and restrictions on
physical activity, translate to further deteriorations in mdx bone strength and geome-
try. Prednisolone is the active form of the drug prednisone, which is the gold standard
of treatment in boys with DMD due to is ability to improve skeletal muscle strength and
function; however, the drug has known deleterious effects on bone. Prior to this work,
the impacts of prednisolone and physical activity on bone in dystrophic mice and DMD
patients were unknown. It was presumed that both factors influenced the deleterious
alterations to bone health, but it was unknown if their actions were independent or
synergistic. This study demonstrated that prednisolone treatment and restricted physi-
cal activity independently accentuated reductions in the strength and geometry of mdx
bone, but had no impact on the material properties of the bone. However, it remains
to be determined if this pattern translates to patients within DMD.
Chapter 5 discusses the findings of a study that investigates the utility of low in-
tensity high frequency vibration to stimulate an osteogenic response in mdx mice and
extensively examines the safety of vibration treatment to the inherently fragile muscle
of dystrophic mice. To address the utility of vibration in stimulating an osteogenic
response, seven different sets of vibration stimuli were compared, where the parameters
of vibration (i.e., acceleration and frequency) were manipulated and mRNA levels of
genes associated with bone formation and bone resorption were measured. This study
determined that 45 Hz at 0.6 g best initiated an osteogenic response and was therefore
considered to be the optimum set of parameters of vibration for mdx mice. Safety of
vibration treatment was addressed in two subsequent studies. These studies determined
4the extent to which vibration at 45 Hz and 0.6 g impacted skeletal muscle contractility
and altered the expression of genes associated with inflammation and myogenesis in
mdx mice as well as two other models of DMD with more severe phenotypes. Com-
bined, these three studies indicate that vibration at 45Hz and 0.6 g is safe for dystrophic
muscle and may be a potential therapeutic modality to improve musculoskeletal health
in DMD.
The paper in Chapter 6 follows directly from the paper in Chapter 5, to determine
the efficacy of longer-term low intensity vibration training to improve musculoskeletal
health in wildtype and mdx mice. The data presented in this chapter suggest that
eight weeks of vibration training at 45 Hz and 0.6 g, 15 min per day, 5 days per weeks,
did not significantly impact tibial bone strength, structure, or trabecular architecture.
Muscle function was also not improved by vibration, however it is important to note that
long-term vibration training was not injurious to inherently fragile dystrophic muscle
and therefor is a safe therapeutic modality. The one positive benefit that arose from
long-term training was that vibrated mice did have smaller fat pads. This may be
potentially desirable in DMD as excessive weight gain results from inactivity and the
use of prednisone.
Chapter 7 serves as an overview of the combined findings presented in this disserta-
tion. The chapter concludes by addressing strategic recommendations for further studies
investigating the utility of vibration, and future directions of bone research in DMD.
Chapter 2
Literature Review
5
6This chapter is intended to provide a background on bone including basic terminol-
ogy and anatomy, the functional and geometric alterations of bone that result in altered
bone strength. The next section will review the role of skeletal muscle in bones func-
tional and geometric alterations that occur with the progression of Duchenes Muscular
Dystrophy in humans as well as in mouse models of the disease. The last section of this
chapter focuses on vibration as a potential therapy and its potential to improve bone
health in various populations.
2.1 Background Of Bone
The following section aims to define the types of bone that were investigated in my dis-
sertation studies, the methods to quantify bone health, as well as the outcome measures
obtained from these methods. Following the introduction of these terms, I will define
and discuss whole bone strength and the two primary contributing properties of bone
strength (i.e., geometric and intrinsic material) along with a brief description of how
these properties are measured. Lastly, I will introduce a the leading theory describing
how bone senses and responds to mechanical loading and the resulting affects this has
on the geometric and intrinsic material properties of bone and therefore whole bone
strength.
2.1.1 Types, Structural Composition and Purpose of Bone
The appendicular skeleton is comprised of two types of bone, cortical (or compact bone)
and trabecular (or cancellous and spongy bone). Cortical bone creates the thick walls
of long bones such as the tibia or femur, while trabecular bone is found at the ends of
long bones as well as along the inside wall of cortical bone, which surrounds the marrow
space (Figure 2.1, and 2.2A). The spatial arrangement and structure of bone varies by
skeletal region, and is customized to the spectrum and magnitude of mechanical loads
placed on the bone. Details on how bone perceives and responds to these loads will be
described later in this chapter.
In general, the thick walls of cortical bone in long bones are arranged in densely
packed concentric circular structures, referred to as osteons. Osteons that are old, or
contain a fracture, are removed and replaced over time via a process called remodeling
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Figure 2.1: Longitudinal cross-section of the femur that denotes the location of cortical
bone in both the diaphysis and epiphysis regions of the femur as well as the location of
trabecular bone in the distal and proximal ends of the femur (as presented in [9]).
(briefly discussed later in this chapter). Thus the concentric layers of an osteon represent
individual layers of new bone, formed from the outside in, by the cells called osteoblasts.
Besides having strength and stiffness provided with concentric circular architecture, each
layer of new bone has differential alignment, which further increases the strength of the
bone and its resistance to loading. Consequently, this arrangement of osteons allows
cortical bone to be both rigid and flexible at the same time. This property of cortical
bone allows it to provide structural support while being able to deform with loading.
Trabecular bone on the other hand, is designed as a lattice of plates and struts that
allows for greater flexibility compared to cortical bone (Figure 2.1A and 2.2B). This
flexibility is advantageous, because it allows the ends of whole bones to simultaneously
withstand multidirectional loading and absorb the energy associated with these loads.
In addition, the arrangement of the horizontal plates and vertical struts can be adapted
to accommodate the dynamic stresses and strains experienced by the bone.
Trabecular bone is often deemed to be more metabolically active and sensitive to al-
terations in mechanical loading than cortical bone; however, this is primarily attributed
to 1) the larger surface area of trabecular bone (eight times larger than cortical bone)
and 2) its proximity to bone precursor cells in the marrow and relatively better nutrient
availability compared to cortical bone.
Prior to providing a background of bone, the following section will review the bone
terms utilized throughout this entire dissertation. In cortical bone (Figure 2.2A), there
are two primary surfaces upon which bone can be added or removed. The first is the
periosteal surface, which is the outermost layer of cortical bone, and the second is the
endosteal surface, which is the innermost layer of cortical bone. The distance between
8Figure 2.2: Panels A and B are exemplar micro Computed Tomography (µCT) images
obtained from the tibial bone of a wildtype mouse at the A) mid-diaphysis (cortical
bone) and B) proximal metaphysis (trabecular bone). A) For cortical bone geometry, the
two surfaces of bone identified along with cortical thickness. B) Trabecular architecture
is defined by trabecular thickness (i.e., the yellow line), bone volume fraction (i.e.,
bone volume per tissue volume, BV/TV), trabecular number (i.e., number of trabecular
within a given region; blue square), and trabecular spacing (i.e., the largest sphere that
fits within the space between trabeculae; red circle). All terms have been defined and
quantified according to international nomenclature and standards [10].
these two surfaces represents the cortical thickness. Additional geometric properties can
be derived from µCT, and include the cross-sectional area of cortical bone as well as
the periosteal diameter. Trabecular bone (Figure 2.2B), is characterized by quantifying
(1) trabecular thickness (2) trabecular bone volume fraction (BV/TV), (3) trabecular
number, and (4) trabecular spacing.
2.1.2 Functional Capacity and Geometric Properties of Tibial Bone
After defining the types of bone and the key terms utilized throughout the dissertation,
it is necessary to introduce whole bone strength and the two primary properties that
contribute to strength (i.e., bone geometry and intrinsic material properties). These
properties can change independently or simultaneously to alter bone strength; therefore,
it is important to quantify both to delineate their respective contributions to alterations
in bone strength. Detailed explanations of these terms and how they are measured
follows below.
9Functional Capacity of Tibial Bones
To assess the mechanical functional capacity of bone, meaning its ability to withstand
loads, mechanical tests such as three-point bending are commonly utilized. For this
functional test, tibial bone limb length is measured, and from this, the mid-diaphysis
(i.e., limb length divided by two) is identified and marked. The tibial bone is then
placed within the three-point bending apparatus on the two lower support beams with
the lateral edge of the tibia facing downward (Figure 2.3A). The bone is centered such
that the upper support beam (i.e., the upper crosshead containing the force transducer)
is directly above the mid-diaphysis of the bone. The crosshead is slowly lowered onto
the bone until the applied load is ∼0.02 N.
When testing is initiated, the crosshead displaces downward at a quasi-static rate,
while the applied force on the bone and the total distance the crosshead has displaced
is recorded. The bone is continually loaded at a constantly slow rate, causing the
bone to bend, until the bone ultimately fails, or breaks. Throughout the entire testing
procedure, the force applied to the bone and the total distance the crosshead displaced
is recorded, and a force-displacement curve is then produced using custom designed
software (Figure 2.3B [11, 12]).
Ultimate load and stiffness are the primary outcome measures of three-point bend-
ing. The ultimate load represents the greatest load the bone can withstand before it
begins to undergo micro-fractures (i.e., the peak of the force-displacement curve), at
which point the force begins to decline (Figure 2.3B). The stiffness of the tibial bone
represents the bones capacity to resist length change, or in this circumstance, bend-
ing. Stiffness is measured as the steepest slope of the force-displacement curve (Figure
2.3B). Secondary measures of three point-bending include deflection to ultimate load
and failure load, as well as energy to ultimate load and failure load. Deflection is defined
as the total distance of crosshead displaced at the time ultimate load and failure load
are reached. This is quantified by measuring the distance along the x-axis of the force-
displacement curve to ultimate load and failure load. The energy measures (i.e., energy
to ultimate load and energy to failure load) are determined by calculating the integral
of the force-displacement curve, or the area under the curve, up to ultimate load and
failure load. Combined, these seven measures reflect upon the structural integrity and
strength of the bone as well as the energy required to break the bone [14]. Detailed
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Figure 2.3: (A) Pictorial representation of a mouse tibial bone undergoing three-point
bending testing. B) Representative force-displacement tracing obtained during testing of
a mouse tibial bone (as presented in [13]). The primary outcome measures derived from
the force-displacement curve include ultimate load, stiffness, and energy and deflection
to ultimate load. The point at which the whole bone fails (i.e., failure load), is also
indicated. Reprinted from [13], Copyright 2011, with permission from Elsevier and
Neuromuscular Disorders.
figures of these secondary measures can be found in Figure 2.1A of Chapter 3.
Further calculations can then be performed to quantify the intrinsic material prop-
erties of the bone, which include ultimate stress and modulus of elasticity. Ultimate
stress and modulus of elasticity are calculated on a mouse-by-mouse basis using classical
beam theory. Ultimate stress is calculated using the following equation: ultimate stress
= (UL*d*L)/(8*CSMI), where UL, d, L and CSMI are ultimate load, medial-lateral
periosteal diameter, bottom support span length, and cross-sectional moment of iner-
tia, respectively. Modulus of elasticity is then calculated using: modulus of elasticity =
(k*L3)/(48*CSMI), where k equals stiffness [11, 12].
The main advantage of three-point bending is that it provides a full characterization
of a bones quality, or more specifically, its functional capacity and intrinsic material
properties. When combined, these measurements provide a unique finger print of bone
health, and allow the investigators to interpret changes in force-displacement curves
that occur with disease, or following treatment. For example, three different types of
bone disease are compared to normal bone in Figure 2.4 [15]. The pathophysiology of
these three diseases are known, and therefore utilizing these finger prints for comparison
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may aid in identifying factors causing ideopathic bone phenotypes.
Figure 2.4: Unique force-displacement curves result from pathophysiologies of bone.
Thus three-point bending is a useful tool to identify how disease has impacted the me-
chanical competence of bone compared to other diseases of known pathology, which can
aid in the identification of appropriate treatment regimens. (Reprinted with permission
from [15], Copyright 1999 American Chemical Society).
The only disadvantage to this technique is that the bone is broken in the mea-
surement process, and as such, it can only be applied ex vivo. The advantage is that
it yields information that cannot be directly measured via any other technique and
it reflects upon the mechanical function of the bone following disease or intervention
treatment. Thus, the characterization of mechanical function can aid in developing ap-
propriate therapeutic regimens. Alternative, non-destructive, surrogates for measuring
bone strength have emerged in recent years with the advancement of imaging techniques
and these new surrogates have been shown to be better correlated to bone strength and
fracture incidence than bone mineral density. These methods include characterizing
bone geometry and outcome measures are described in the following sections.
Current Imaging Techniques and the Utility of Measuring Geometric Prop-
erties of Bone
The two most commonly used bone-imaging techniques in the literature include Dual-
Energy X-ray (DXA) absorptiometry and computed tomography. These techniques
provide complimentary information pertaining to skeletal health; however the outcome
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measures associated with computed tomography are becoming increasingly better in-
dicators of skeletal health than DXA. Simply stated, DXA provides information about
how much bone is present in various regions of the skeleton, and computed tomography
provides information for where this mass is structurally distributed in space. Therefore
computed tomography provides and indication of the geometry, or the structural shape,
of the bone which is one of the two primary factors contributing to bone strength.
The following section is aimed to describe these two imaging techniques and how they
are utilized to assess of bone health and provide an indication of bone geometry and
strength.
Dual-Energy X-ray Absorptiometry
Initially measurements of bones geometric properties were estimated by measuring pe-
riosteal diameter and cortical thickness with calipers on radiographs [16]. Based on
these measures, cortical area and thereby strength of the bone could be calculated, pro-
viding a rough estimate of alterations in bone geometry over time. Several years later,
dual-energy x-ray absorptiometry (DXA) became widely available to quantify bone mass
and areal bone mineral density (Figure 2.5). The primary advantage of DXA is that
bone mass and areal bone mineral density (i.e., density of bone mass within a given area,
rather than a traditional volumetric measure) are both strongly correlated with fracture
risk [17]. Consequently, bone mass, and areal bone mineral density are commonly used
surrogates for whole bone strength.
A shortcoming of the DXA technique is that the geometry of the bone, where the
bone mass is distributed in space, is not measured. To aid in this explanation, compare
the three theoretical bones in Figure 2.6. As measured by DXA, each of the theoretical
bones are equal in terms of their bone mass, however due to differences in how the
bone mass is distributed in space, the cylinders do not have equivalent strength. As a
result, better imaging techniques have been devised to overcome this problem, and are
discussed below.
Computed Tomography
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Figure 2.5: DXA quantifies the amount of bone mass (i.e., regions of white) within a
given skeletal region. The density of bone is represented by the intensity of white within
a single pixel. For example, notice the difference in pixel intensity between the skull and
spine. Fat mass and lean can also be quantified using this technique. (Image courtesy
of Petit, M.A., 2009).
Figure 2.6: Three bones with equivalent bone mass are depicted, however the spatial
distribution of this mass differs between bones A, B and C. Distribution of bone mass
further away from the bones neutral axis (i.e., the center of the bone) translates to
improvements in bone strength. For example, the relative bending strengths are 4 to 8
times larger in bones B and C, respectively, compared to bone A. (Image courtesy of
Petit, M.A., 2009).
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Currently four types computed tomography imaging techniques are utilized to char-
acterize the geometry, or the shape, of bone. These techniques include peripheral
quantitative computed tomography (pQCT), micro-computed tomography (µCT), ultra
computed tomography (ultraCT), and nano-computed tomography (nCT). The primary
differences between these techniques are the size of the object that can be imaged (e.g.,
a human tibia versus a mouse tibia) and the resolution of the image (i.e., size of the
3-dimensional element which measures bone. A small voxel size translates to a more de-
tailed image of the bone and vice versa). The two options for human usage (whole bone)
are pQCT and ultraCT, whereas µCT and nCT are primarily used for bone biopsies in
humans, or on whole bones from smaller animals such as rodents.
The bore size (i.e. the circular opening in the CT, where limbs are placed to be
imaged, see Figure 2.7A) limits the size of the bone that can fit into the machine. For
example, in the pQCT shown in Figure 2.7, the distal femur, or the entire tibia or radius
of humans can fit within the bore. For µCT and nCT, the maximum specimen size is
considerably smaller. The maximum specimen size that fits within the bore of our µCT
is 36.9 mm x 80 mm. The advantage of the smaller bore size is that the resolution of the
image improves as voxel (i.e., data element that quantifies bone within a 3-dimensional
grid) size decreases. For instance, to characterizing trabecular architecture in young
mice with an average trabecular thickness of 41 µm [13], the 12 µm voxels size of µCT
would have at least three voxels describing the thickness of the trabeculae, whereas, a
single voxel by pQCT (i.e., 70 µm) would span the entire thickness and therefore provide
less information about how the bone is distributed in space. With pQCT, trabecular
bone volume is measurable; however the voxel size is too large to characterize trabecular
thickness, number or spacing. In rodents, µCT has the capacity to sufficiently measure
both trabecular architecture and cortical bone geometry.
Each of the computed tomography techniques images the bone in sequential three-
dimensional slices of bone (Figure 2.7B), with the height of the slice representing the
resolution (or voxel size). These sequential images are then stacked on top of each
other and then reconstructed using computerized software (Figure 2.7C). The outcome
measures of pQCT include: bone volumetric density (vBMD), cortical bone geometry,
and calculated surrogates for of bone strength. The pQCT derived surrogates for bone
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strength were not utilized for the present dissertation, and therefore will not be dis-
cussed. The outcomes of µCT include: vBMD, cortical bone geometry, and trabecular
architecture (as defined in Figure 2.2 of the current chapter). The commercial availabil-
ity of ultraCT and nCT systems has improved in recent years; however, techniques have
not been utilized to date within muscular dystrophy nor vibration and consequently the
use of these two techniques will not be further discussed.
Figure 2.7: (A) Image of a pQCT, showing the size of the bore (i.e., central aspect of
the machine where the bone is placed to be imaged). Exemplar images of tibial bones
from B) human imaged by pQCT and C) mouse imaged by microCT ex vivo. Panel
C also defines the three skeletal regions of mouse tibial bone measured throughout
this dissertation, as well as exemplar three-dimensional reconstructions of those skeletal
regions of bone.
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Cross-sectional moment of inertia
The primary outcome of interest from µCT is the minimum principle cross-sectional
moment of inertia (CSMImin, referred to as CSMI for the remainder of this thesis)
because it is a surrogate for whole bone strength [14]. This measure best corresponds to
the moment of inertia about the bone bending axis during three-point bending testing.
This variable is derived using engineering principles which quantifies each individual
voxels moment of intertia relative to the bones neutral axis. The inertia values for
all voxels within a slice of bone are then summed within a CT slice and then average
across the entire region of interest to provide a precise estimate of bone strength [14].
After applying this calculation to the three bones illustrated in Figure 2.6, it becomes
immediately apparent that bone C has a eight-fold increase in resistance to bending
compared to bone A, thereby highlighting the importance of altered bone geometry on
bone strength.
2.2 Regulation of Bone Geometry and Architecture In Re-
sponse to Mechanical Loading
After establishing that bone strength is measured directly by mechanical testing and
indirectly through imaging techniques, the mechanisms by which bone alters its mass,
shape and strength can now be introduced and later applied to disease states. Bone
is a dynamic structural material, in that it constantly makes adjustments to preserve
its mechanical competence based on the prevailing loads it endures. In addition, bone
is considered a minimal-mass structure [18], meaning that bone aims to be as strong
and efficient as possible at the lowest metabolic costs associated with maintaining bone
mass. Thus, as previously alluded to, expanding periosteal bone diameter is one means
of improving bone strength without increasing bone mass, and therefore, metabolic
demand.
Mechanical loading is theorized to be the primary factor that stimulates bone to self-
regulate its functional, geometric, and intrinsic material properties. Prior to discussing
these processes, it is necessary to define: how mechanical loading is sensed by the bone
tissue, the cells within bone tissue that sense the mechanical load, and how the bone
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responds to loading including the theory that governs this response.
2.2.1 Definition of Strain
The quantifiable unit of mechanical loading in bone is the strain applied to the bone.
Prior to defining strain, it is necessary to define stress. Stress in any material is defined
as the load per unit area. Once stress is placed on the bone, the bone deforms and the
resulting change in length caused by the load, relative to the original length, represents
the applied strain and is reported in units of microstrain (or may be denoted as µ).
The mechanism(s) by which strain is sensed by the bone cells remains elusive. How-
ever, osteocytes have been theorized to be the primary sensors of mechanical loading
(Figure 2.8). Osteocytes are presumed to be the mechanosensors of mechanical loading
for the following reasons: (1) osteocytes are the most abundant cell type within bone, (2)
osteocytes are strategically placed within the bone matrix and have vast 3-dimentional
communication networks with neighboring osteocytes (via gap junctions), and (3) os-
teocytes can live up to 15-20 years without replication [19, 10].Thus osteocytes are the
best candidates for sensing mechanical loading-induced strain as well as initiating bone
remodeling upon their death.
Figure 2.8: Osteocytes and their canaliculi (i.e. cell processes) are shown in black, where
the cortical bone is white. (Reprinted from [20] with permission from Elsevier).
The importance of osteocytes in the sensation and response of bone to mechanical
loading has only begun to emerge in the past decade. For example, reductions in os-
teocyte number and sensitivity are thought to be contributing factors to the decline in
bones response to mechanical loading with age. Specifically, the viability of osteocytes
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declines by 15% with age in adulthood [19]. In addition, others have noted lower osteo-
cyte density in deep bone (>45µm from the surface) compared to more superficial bone
[21], which is hypothesized to impact how bone perceives and responds to mechanical
loads. Combined, age-associated bone loss may be partially attributed to a decreased
number of viable osteocytes as well as an altered strain sensing capacity, which may
translate to a blunted response to mechanical loading, resulting in a reduction in bone
mass.
2.2.2 Mechanostat Theory of Bone Self-Regulation
After establishing that bone has the capacity to perceive mechanical loading via os-
teocytes, the response of osteocytes, pertaining to the regulation of bone mass and
structure, to loading environments can now be discussed. The proposed theory of adap-
tation is referred to as the Mechanostat theory, developed by Harold Frost [22]. The
basis of the Mechanostat theory is that a particular bones typical loading environment
will dictate the bones mass and where this mass is structurally placed.
The Mechanostat theory suggests that bones response to mechanical loading is sim-
ilar to that of a thermostat. To set the stage, consider that the thermostat in a home is
set to 72 oC. When the temperature is below 72 oC, error signals, or negative feedback
loops, will be transmitted from thermostat to turn the furnace on until the temperature
in the room reaches the desired threshold. The same applies if the temperature were
to exceed 72 oC, which could initiate an error signal to turn the furnace off. In bone,
strain levels are the stimulus for negative feedback loops (Figure 2.9). Specifically, when
strains perceived by osteocytes are higher than normal, osteocytes will initiate cellular
responses to increase bone formation in effort to lower the strain magnitude associated
with a given mechanical load. This pathway will continually be activated until enough
bone is formed to sufficiently reduce the stress applied to the bone, and therefore bring
the associated strain of a given mechanical load, back within the typical range of strain
levels. The opposite also occurs when strains are lower than normal. Specifically, fol-
lowing reductions in typical strain levels, bone will undergo resorption (i.e., the removal
of bone mass) causing stress levels, and therefore strain to increase.
Another way the Mechanostat theory has been presented it shown in Figure 2.10. In
this diagram, normal loading patterns, or typical strain levels, are shown in the central
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Figure 2.9: The Mechanostat theory suggests how bone responds to alterations in typi-
cal levels of mechanical loading. For example, bone deposition results on the periosteal
surface when strain magnitudes exceed typical levels. This increase in bone area acts
to decrease the stress and strain associated with a given load and therefore, the bone
returns to the initial typical strain level. The opposite occurs during periods of un-
loading, where the reduction in typical strain levels causes bone to be removed. As
a result, strains that were previously considered typical will now be perceived by the
bone as elevated strain, and will result in bone deposition. (Modified with permission
and Copyright 1984 from Springer Science and Business Media and the Calcified Tissue
International [23]).
rectangle. When strains are lower than normal, the bone is considered to enter a stage
of disuse (e.g., inactivity, bed rest or disease), and bone loss will occur through a process
called bone remodeling (described later in this chapter). As a result, bone strength will
decrease relative the amount of inactivity (shown as the black line in Figure 2.10). In
response to overload, bone modeling is initiated (described later in this chapter), which
typically places bone on the periosteal surface to increase the diameter and strength.
Further detailed explanations and evidence for overload and disuse follow in the next
two sections.
2.2.3 Bone Modeling versus Remodeling
Beyond osteocytes, there are two other primary types of cells in bone: osteoclasts and
osteoblasts. Osteoclasts resorb, or remove, bone that is old, damaged, or no longer
needed. Osteoblasts synthesize new bone and regulate the deposition of mineral within
bone. These cell types are then involved in two processes called bone modeling and bone
remodeling. Bone modeling occurs in response to two primary stimuli: longitudinal limb
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Figure 2.10: When mechanical loading results in strains that exceed typical levels, the
bone enters a stage of overload, causing the bone to deposit bone on the periosteal
surface (i.e., modeling). The increase in bone mass further from the neutral axis also
increase bone strength. The opposite occurs during periods of unloading, where the
reduction of strain levels from normal causes bone to enter a stage of disuse, where
bone is removed, and bone strength is detrimentally compromised. (Reprinted and
Modified from [24]), Copyright 2002, with permission from Elsevier).
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growth during childhood, and overload in adults.
During childhood bone modeling, osteoclasts and osteoblasts are simultaneously re-
moving and forming bone; however, these cells are working on two different surfaces
of the bone. This approach results in bone growth in length and width, by simply
removing bone from one region of bone and placing it in another. Specifically, osteo-
clasts remove bone from the inner surface of the marrow cavity as well as the epiphysis
(Figure 2.11A). This bone material is then utilized by osteoblasts to place bone on the
periosteal surface and on the ends of the bone to increase the width and the length
(Figure 2.11A), resulting in increased bone strength. Beyond longitudinal growth, bone
modeling occurs on the periosteal and endocortical surfaces, but at much slower rates
(Figure 2.11B). While this is advantageous in childhood, the bone eventually reaches a
point of diminishing returns, and continued modeling may actually predispose the bone
to fracture late in life.
Bone remodeling on the other hand, removes and replaces bone that is old or dam-
aged with new bone. Specifically, osteoclasts and osteoblasts work in tandem to each
other on the exact same region of bone (Figure 2.12). Through this process, the entire
skeleton is completely replaced approximately every 10 years. Thus, skeletal issues with
age are not due to the bone being old, but rather inefficient bone remodeling (e.g., bone
resorption may exceeds bone formation leading to net bone loss) or alterations in the
material properties of bone (i.e., minor substitutions in the chemical structure of bone
material, which change the structural integrity of bone material). The other case in
which bone remodeling is commonly initiated is disuse. In disuse-mediated remodeling,
the bone that is resorbed is no longer needed due to the decreased stress/strain associ-
ated with disuse, and is removed to lower the metabolic cost of maintaining this bone
tissue. Bone formation may follow to a minimal extent.
2.2.4 Overload: Mechanical Loading is Higher than Normal
Overload, or overuse, is a term typically utilized to describe periods in which the bone ex-
periences strains that are higher in magnitude than normal. Animal models (e.g., rat and
turkey) have been employed to characterize the response of bone to overloading[28, 29].
An example of functional and geometric benefits of overloading bone is demonstrated
in Figure 2.13A, in which external loading was applied to the right ulna of rats [28].
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Figure 2.11: A) Growth-induced alterations in cortical bone structure (i.e., increase in
age from left to right) are attributed to the expansion of the periosteal surface due
bone formation as well as expansion of the marrow cavity associated with endocortical
resroption. (Reproduction with permission and Copyright 2002 from John Wiley and
Sons and the Journal of Bone and Mineral Research [25]). B) Age and sex differences in
periosteal bone formation and endocortical resorption in long bones across the lifespan.
(Reproduction with permission and Copyright 2008 from Springer Science and Business
Media and the Journal of Bone and Mineral Metabolism [26]).
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Figure 2.12: Bone remodeling is initiated by the removal of bone tissue by osteoclasts.
At this same region of bone, the resorption pit created by osteoclasts is slowly filled
in one layer at a time by osteoblasts (i.e., labeled osteoid). (Image courtesy of IBMS
BoneKEy, [27]).
Histological findings indicate that bone apposition, or formation, was apparent in the
loaded limb compared to the non-loaded limb (i.e., region of bone between the red and
green labels in the right panel of Figure 2.13B). Consistent with other animal models,
bone accumulation was not random, but was strategically placed in regions where strain
levels were highest. The net result of overload is increased CSMI and bone strength
of the loaded limb, making the bone structurally and functionally adapted to the new
loading environment compared to the non-loaded limb.
Figure 2.13: (A) The rat ulnar mechanical loading model developed by Turner and
Robling applies a strain directly the bone. This technique is typically performed on
a single forearm, such that the contralateral limb serves as a control. B) In response
to this form of loading, bone formation strategically occurs in regions of the ulna that
experienced overload. Bone formation is indicated by dynamic histomorphometry, which
fluorescently labels the surfaces of bone at baseline (i.e., red line) and one day prior to
sacrifice (i.e., green line). The region of bone formed between the red and green labels
represents bone formation. (Reproduced with permission and Copyright 2002 of the
Journal of Bone and Mineral Research [30]).
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2.2.5 Disuse: mechanical Loading is Lower than Normal
On the other hand, during periods of disuse such as immobilization (e.g., casting), bed
rest, space flight, disease, or hindlimb unloading, the bone endures strains that are
lower than normal. As a result, the bone is essentially over-adapted to the new loading
environment (there is more tissue than what is needed to support the reduced function
of the bone), which places an unnecessarily high metabolic demand on the tissue [31].
This triggers a cascade of events that will remove unnecessary bone mass, typically from
the endocortical surface or within the cortical wall. Radiographic comparisons of young
dogs casted for 40 weeks compared to controls demonstrates this dramatic loss of bone
that results from periods of disuse (Figure 2.14)[32].
Figure 2.14: Radiographic images depicting the bone loss that resulted from 40 weeks
of casting (bone on the right compared to the healthy bone on the left) in young dogs.
(Reproduced with permission and Copyright of the British Editorial Society of Bone
and Joint Surgery [32]).
As bone enters a stage of disuse, both trabecular and cortical bone will be lost;
however, the rates and timing of bone loss are different for each type of bone. Specif-
ically, trabecular bone loss begins in the acute stages of immobilization, when bone
formation rates decrease [33, 34, 35, 36, 37] and trabecular resorption rates increase
[35, 36, 37]. The combined result is a decline in trabecular number, connectivity, and
bone area [35]. Disuse-mediated bone loss has also been shown to reduce the mechanical
competence of trabecular bone by 26-72% compared to controls [38]. Bone loss from
hindlimb unloading in rodents and casting in dogs has been reported to cease between
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10-18 weeks, indicating that enough bone loss has occurred to re-establish a balance be-
tween bone mass and the stresses and strains, as previously described by Mechanostat
theory (Figures 2.9 and 2.10) [39, 35].
Compared to trabecular bone, periosteal cortical bone adapts to disuse via a two-
step process with formation nearly ceasing within two weeks of disuse followed by a
significant increase in endocortical resorption (see example in Figure 2.15) [35, 32]. As
a result, the periosteal diameter remains constant, while the marrow cavity expands
to reduce cortical thickness. Bone resorption in cortical bone has been suggested to
stabilize around 18 weeks in hindlimb unloading models [35], however up to 60 weeks is
required in casting models [39].
Figure 2.15: Images represent transverse histological sections of cortical bone from dogs
that have either undergone hindlimb unloading (bone on the right) or typical loading
patterns (bone on the left). Hindlimb unloading deleteriously altered bone geometry,
as indicated by the lack of periosteal expansion and increased marrow cavity. This
results in a thinner and smaller bone. (Reproduced with permission and Copyright of
the British Editorial Society of Bone and Joint Surgery [32]).
Typically, the net bone loss during periods of disuse is reversible upon re-ambulation
[40, 41]. Applying the Mechanostat theory to this situation, would suggest that re-
ambulation initiates a state of overload, driving bone formation to reduce the newly-
increased strains applied to the bone during walking. However in cases such as spinal
cord injury or progressive muscle diseases like Duchene muscular dystrophy, ambulation
may not be regained and thus, alternative means of preserving bone mass are warranted.
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2.3 Background of Skeletal Muscle and Muscle Diseases
Related to Bone
2.3.1 Skeletal Muscle Function
A skeletal muscle is composed of a series of nested bundles. These bundles sequentially
decline in size with fascicles being the largest, followed by muscle fibers and myofibrils
being the smallest. The contractile elements within each myofibril (i.e., myosin and
actin) are arranged into structures called sarcomeres, which align in series and in parallel
(Figure 2.16). The activation of cross bridging between actin and myosin, results in the
production of force. The contractile action of the muscle also results in the synchronous
folding of the sarcolemma, or the sheath surrounding the myofibril. Through this action,
a fraction of muscle force is transmitted longitudinally within the muscle to the tendon,
while the majority of the force is transmitted laterally to the sarcolemma.
The key structural elements that transfer force laterally from myofibrils to the sar-
colemma are found in the dystroglycan complex and are referred to as costameres (Figure
2.17). The function of costameres is to: 1) physically attach peripheral sarcomeres to
the sarcolemma and coordinate synchronous folding of the sarcolemma, and 2) connect
neighboring sarcomeres to one another facilitating maintenance of coordinated sarcom-
ere length during activation [43]. Thus, the contractile elements within sarcomeres
produce force that is transferred laterally by structural elements to the sarcolemma and
tendon resulting in the transmission of stresses and strains to the bone.
2.3.2 Skeletal Muscle Disease
In the previous section, the function of the dystroglycan complex and the costamere
were introduced and their role in stabilizing muscle fibers and transmitting force was
emphasized. This is important because various mutations are known to occur in cer-
tain proteins in the dystroglycan complex, resulting in the development of muscular
dystrophies. Depending on the location of the mutation, there is either a lack of force
production or an absence of force transmission [43].
The most common muscular dystrophy is Duchene Muscular Dystrophy (DMD),
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Figure 2.16: Cross bridging of the myosin and actin proteins in the sarcomere results in
force production, which is then transferred laterally to the sarcolemma. (Reproduction
with permission and Copyright 2012 of Wiley Periodicals, Inc. [42]).
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Figure 2.17: Costameres (denoted by green lines) serve as tethers between the z-disk
of the myofibril and the sarcolemma, and thus are circumferentially arranged. These
protein complexes act to transfer the force produced by the contractile proteins within
the sarcomeres laterally to the sarcolemma. (Reproduced with permission from the
Journal of Biological Chemistry [43]).
which impacts 1 in 3500 male births [44]. DMD is caused by a mutation in the dys-
trophin gene (located on the X chromosome), which encodes for the production of the
dystrophin protein. The presence of a mutation does not prohibit the production of
the protein dystrophin; however, the structure and function of the protein are affected.
The dystrophin protein is responsible for 1) organizing costameres and maintaining sar-
colemma integrity [45, 46] and 2) limiting the movement of molecules into and out of
cells [47, 48]. Thus the lack of dystrophin causes sarcolemma instability which leads to
a host of downstream events including reduced force production [49].
While the complete pathophysiology of DMD remains elusive, DMD is characterized
by contraction-induced muscle injury resulting in a loss of force production [45, 50, 51].
As the disease progresses, damaged contractile elements are replaced by connective tissue
and fat [45, 50, 51] giving the muscle a pseudo-hypertrophied appearance beginning
around the age of 4 years. The lower extremities tend to be affected by disease first and
proximal muscles are more affected than distal muscles [51]. Contractures of the elbows,
knees and hips also develop [51], resulting in the loss of independent ambulation and
making boys wheelchair bound by the early teenage years [[52, 44, 53]. As a consequence
of disease progression, boys with DMD become progressively inactive and unable to
independently perform activities of daily living.
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2.3.3 Effects of Duchene Muscular Dystrophy on bone
As dystrophic muscle becomes weaker, fewer and less forceful contractions are applied
to the bone. This in theory causes the bone to enter a stage of disuse resulting in bone
loss. The majority of studies to date investigating skeletal health in boys with DMD
have focused solely on areal bone mineral density (aBMD) determined by DXA as an
indicator of bone health [54, 2, 1, 55, 56] as the use of pQCT to characterize bone
geometry have only been reported in abstract form [5, 6]. These data consistently show
that aBMD is reduced in various skeletal regions of boys with DMD compared to age
matched peers (exemplar data are shown in Figure 2.18).
The importance of muscle-induced mechanical loading in maintaining skeletal health
is also highlighted in Panel B of Figure 2.18. Specifically, following the loss of indepen-
dent ambulation at ∼10 years of age (range: 7.4 to 11.6y), hip aBMD in boys with DMD
(i.e., filled squares) begins to drastically deviate from their peers (i.e., open circles) [55].
Similar findings have been reported for the hip, where the bone mineral density values
for boys with DMD fell nearly 4 standard deviations below the mean of their peers after
becoming wheelchair bound [2]. Combined, these data highlight the secondary losses
in bone mass that result from the loss of muscle strength and the inability to perform
simple activities such as walking or standing.
The main functional consequence of bone loss is that the weaker bone is predisposed
to fracture. Therefore, it follows that, boys with DMD have an elevated risk for frac-
ture (18-44%) compared to matched controls, which is more pronounced as the disease
progresses [2, 1, 3]. These fractures predominately occur in the lower limb after falling
from standing or sitting height, classifying them as fragility fractures [3, 57].
In an effort to impede the progression of muscle deterioration, the glucocorticoid
prednisone is the treatment of choice. Prednisone has been shown to thwart muscle
deterioration, improve physical endurance, decrease falls, improve stair climbing, and
prolong independent ambulation in patients with DMD [58, 59, 60]. Simultaneous to
these benefits to muscle tissue, glucocorticoids induce osteoporosis and increase fracture
risk by increasing osteocyte and osteoblast apoptosis as well as extending the lifespan of
osteoclasts [61, 62, 63]. Specific to DMD, the use of glucocorticoids has been shown to
accentuate reductions in bone mass and density [1, 55, 64], increase the incidence of long
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Figure 2.18: Each data point represents a childs bone mineral density for (A) the total
body and (B) the hip. Boys with DMD are shown as filled squares and their age-
matched peers as open circles. The differences in bone mineral density between groups
increased with age, however the largest deviations occurred in the hip around the time
that ambulation was lost (i.e., 10 years of age). (Reprinted from [55], Copyright 2007,
with permission from Elsevier).
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bone fractures by nearly three-fold [64], and provoke the emergence of vertebral com-
pression fractures which do not occur in DMD patients not treated with glucocorticoids
[64, 65]. These results suggest that altered osteoblast and osteoclast viability disrupts
the homeostasis of bone remodeling and therefore may translate to compromised bone
structure and strength. Considering that bone is inherently compromised in strength
and has altered geometry in individuals with DMD [13, 5, 6, 7, 8, 66, 4], the addition
of glucocorticoids and reduced physical activity may cause further decrements to the
structural and material integrity of bone. The combined contributions of these insults
have not been thoroughly investigated prior to our work (See Chapter 4 for details).
2.3.4 Dystrophic Mouse Models
Two established mouse models of DMD (i.e., mdx and dko mice) are often utilized to
characterize the disease as well as identify potential therapies. The mdx mouse model
has a single point mutation in the dystrophin gene and has been shown to develop many
of the hallmark characteristics of DMD including progressive muscle weakness [67]. The
severity of the diseases, and therefore the phenotype, of mdx is mild compared to boys
with DMD. The mild phenotype is attributed to the upregulation an analogous protein
of dystrophin, called utrophin. Utrophin in mdx mice functions similar to dystrophin
and as such is able to rescue the phenotype. This utrophin-induced reversal of the
disease typically begins around 10 weeks of age. As a result, the mdx model may not
be suitable for investigating long-term deteriorating bone health in DMD.
The dko model on the other hand is a more severe model of DMD and its phenotype
better mimics DMD than does the mdx mouse model. Dko mice are deficient in both
dystrophin and utrophin, and therefore lack the ability to rescue the muscle disease
and reverse the phenotype, making the model more similar to the disease progression
observed in humans. In these mice, muscle weakness begins early in life and progresses
quickly leading to joint contractures and premature death at ∼10 weeks of age [68].
At the time of my dissertation proposal, only two studies had utilized mdx mice to
investigate bone health [7, 8] and none had utilized the dko mouse model. Anderson
reported that tibial bones were weaker in 4- and 18-week old mdx mice, compared to
age-matched, wildtype mice [7]. The reduction in bone health was indicated by smaller
ultimate loads, smaller cross-sectional areas, and thinner cortical walls. In contrast,
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Montgomery et al. found that 16-week old mdx mice had stronger, wider and denser
femurs compared to those from wildtype mice [8], but these genotypic differences were
abolished after adjusting for the greater body mass of the mdx mice. Thus, it remained
elusive whether or not mdx bones were functionally compromised as a secondary con-
sequence of the muscle disease.
The results of Montgomery et al. and Anderson et al. provided a foundation of
bone geometry and functional properties in mdx mice; however, better characterization
of bone was warranted especially in the window of time where functional declines in
muscle are taking place (i.e., less than 12 weeks of age). To address this, my preliminary
work compared (1) tibial bone geometry and (2) trabecular bone architecture of both
mdx and dko mice at 7-weeks of age relative to wildtype mice. My data indicate that
mdx mice have reduced: bone strength, cortical geometry and trabecular architecture
compared to wildtype mice (described in Chapter 3). This study also characterized the
dko mouse model of DMD and established that dko mice are more severely affected than
mdx mice
In a subsequent study, discussed in Chapter 4, I showed that reduced physical ac-
tivity and prednisolone treatment (i.e., the active form of the drug prednisone) inde-
pendently accentuate reductions in bone strength and geometry in mdx mice, but do
not influence the intrinsic material properties of the bone tissue. The effects of phys-
ical inactivity had greater impacts than prednisolone, highlighting the importance of
maintaining physical activity levels in patients with DMD. Because DMD is acceler-
ated by exercise-induced injury, alternative mechanisms for improving bone strength
are warranted that do not necessarily require high-force muscular contractions. The
development of low magnitude high frequency vibration could become an attractive
therapy for those with DMD as it directly applies mechanical loads to the bone, equiv-
alent in strain magnitude as those produced by postural-muscle activation patterns,
while circumventing the need for the muscle to actually contract.
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2.4 Low Intensity, High Frequency Mechanical Vibration
Low intensity vibration as a therapeutic modality has been receiving increasing attention
as a non-invasive tool to improve musculoskeletal health, despite a lack of clear mech-
anistic pathways. Chronic exposure to short bouts of low-acceleration, high-frequency
vibration have been shown to improve muscle power and strength [69], thwart bone
loss [70, 71, 72], provoke an anabolic bone response [73], and enhance bone strength as
well as reduce fracture risk [74]. The follow section will provide a brief background of
the most commonly theorized mechanisms of action and why vibration is an attractive
modality for DMD.
Bones response to mechanical loading is governed by the Mechanostat theory (dis-
cussed in Figures 2.9 and 2.10). It is important to realize however, that bone responds
to a continuum of strains (i.e., 10 to >2000 microstrains), and does not preferentially
respond to high intensity strains. This response to mechanical loading is governed by
an inverse power law (Figure 2.19), which indicates that a few high-intensity loads are
just as effective to maintain bone strength as thousands of low-intensity loads (i.e., pink
line in Figure 2.19) [75]. Thus, to maintain skeletal health 1-3 high-intensity loads, such
as running or jumping, may be just as effective as the activation of postural muscles
(i.e., 10 microstrains) ∼800,000 times per day.
Low intensity, high frequency vibration operates on the low intensity microstrain
end of the inverse-power law continuum, and has been suggested to act as a surrogate
for muscle contractions [76]. Activation patterns of postural muscles during vibration
are similar to those produced during standing [77]. Thus, vibration is an attractive
therapeutic modality to maintain, and potentially improve, bone health in disease pop-
ulations where muscle strength and function, and thus bone are impacted. For DMD
patients, who are advised to avoid high intensity loads due their propensity to cause
muscle damage, the low intensity nature of vibration makes it an attractive therapeu-
tic modality to preserve bone health, especially as disease progression causes muscle
weakness and physical inactivity increase.
Despite reports of beneficial effects of vibration (see Appendix 1 for results in ro-
dents), the overall efficacy of low intensity vibration has been challenged due to incon-
sistent findings across studies and the lack of clinically-meaningful results across various
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Figure 2.19: Bones response to mechanical loading has been shown to follow an inverse
power law between the cycle number and strain magnitude. Maintenance of bone mass
exists on a continuum (denoted by the pink line), and therefore a number of distinct
loading strategies can be utilized to prevent bone resorption. Thus four cycles at 2,000
microstrain may be just as effective as hundreds of thousands of cycles of signals of well
below 10 microstrain. In addition, falling below or above the preferred strain continuum
would result in bone resorption or formation, respectively. (Reprinted by permission
from Macmillan Publishers Ltd: Nature Reviews Rheumatology [75], copyright 2010).
35
populations [78]. This lack of efficacy may be the result of applying sub-optimal vibra-
tion parameters, such as frequency and acceleration, to the model of interest. Judex et
al, for example, found that the osteogenic response to a single set of vibration param-
eters in differed greatly among three commonly used genotypes of healthy mice [79].
Similar findings have been noted in humans. Specifically, the musculoskeletal response
to vibration exposure appears to be more robust in compromised skeletons such as those
of disabled children, postmenopausal women or women with low bone mass, compared
to healthy skeletons [80, 81, 82]. It is reasonable to assume that the musculoskeletal
systems response to vibration may not be equivalent across disease models, sexes, age
ranges or other modifiable factors. This highlights the importance of individualizing
parameters of the mechanical signal delivered by vibration equipment to the model or
disease of interest in order to evoke the greatest response. The issue is addressed in
further detail in Chapter 5. Upon determining osteogenic parameters of vibration for
dystrophic mice, the efficacy of 8 weeks of vibration training to alter bone strength,
geometry and material properties in mice is addressed in Chapter 6.
2.5 Summary
Mechanical loading plays a substantial role in determining bone strength, geometry, and
material properties. Declines in bone health are known to occur following reductions
in mechanical loading (i.e., casting, bed rest, and hindlimb unloading) and are thought
to be predominately attributed to alterations in muscle-induced loads applied to bone.
Thus, in muscle diseases such as DMD, disuse-mediated bone loss is hypothesized to be
initiated in response to progressive muscle weakness and physical inactivity. The loss
of bone mass likely deleteriously impacts bone strength and would contribute to the
increased rate of fragility fractures that are known to occur in this population.
Low intensity, high frequency vibration is hypothesized to act as a surrogate for
muscle-induced loading of bone, making it an attractive therapeutic modality to pre-
serve, and perhaps improve, bone health in DMD. Chronic exposure to short bouts
of vibration has been shown to improve muscle power and strength [69], thwart bone
loss [70, 71, 72], provoke an anabolic bone response [74], and enhance bone strength as
well as reduce fracture risk [74]; however, it remains to be determined how efficacious
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vibration training would be for musculoskeletal health in DMD
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3.1 Abstract
The primary purpose of this study was to determine if tibial bone strength is compro-
mised in dystrophic mice and if so, what geometric and material properties contribute.
Results of three-point bending tests showed that tibia of mdx and dko (dystrophin- and
utrophin-deficient) mice had up to 50% lower strength and stiffness compared to wild-
type mice. Micro-computed tomography indicated that dystrophic tibia had reductions
of 6-57% in cortical cross-sectional moment of inertia and cross-sectional area. Meta-
physeal trabecular bone morphometry was also altered up to 78% in dystrophic mice.
Bone-to-muscle functional ratios (i.e., three-point bending measures:muscle strength)
indicated that bone strength was relatively high in 7-week-old dystrophic mice com-
pared to muscle strength, but ratios were similar to wild-type mice by 24-months of
age. Thus, as in boys with Duchenne muscular dystrophy, young dystrophic mice have
compromised bone strength; these models may be useful for designing therapeutic reg-
imens aimed at improving the skeleton.
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3.2 Introduction
Bone fractures are on the rise in the nearly 8,000 boys in the United States affected by
Duchenne muscular dystrophy (DMD), with little progress being made toward remedia-
tion [2, 1, 3, 83]. DMD is characterized by progressive muscular weakness attributed to
contraction-induced muscle injury followed by inefficient repair [84]. Thus as the disease
progresses, boys become less physically active and unable to perform activities of daily
living [53, 52, 44], both of which reduce the frequency and magnitude of mechanical
loads placed on bone. As a result, bones should enter a stage of disuse, resulting in
bone loss and structurally weakened bones that are more prone to fracture. Indeed,
fracture incidence in boys with DMD is reported to be between 18-44%, where higher
incidence rates parallel increases in age, physical limitation and disease state [2, 1, 3].
Fractures typically occur in the lower extremities after falling from standing or sitting
height [3, 57], indicating that bone strength is compromised. This loss of bone strength
may be due to altered bone geometry and/or other extrinsic or intrinsic material prop-
erties (e.g., density or composition of the bone). Dual energy X-ray absorptiometry
(DXA) has been utilized to monitor the loss of areal bone density in various skeletal
regions with age in DMD [2, 55], but the relative contribution of bone loss and that of
compromised bone geometry and material properties to bone strength have not been
evaluated in DMD. Delineating the roles of these factors will provide a better indication
of whole bone function and fracture risk in the context of muscular dystrophy.
Mouse models of DMD are available and these could aid in the assessment of the
diseases effect on bone strength and its underlying mechanical determinants including
geometric and intrinsic material properties. There have only been two studies on bone
in a DMD mouse model and both utilized the mdx mouse [7, 8], the most commonly
used animal model of DMD. Similar to boys with DMD, mdx mice have dysfunctional
dystrophin protein, and as a result develop characteristic muscle weakness early in life,
i.e., between 15-20 days of age [85]. Anderson et al. reported that the tibia is weaker in
4- and 18-week-old mdx mice, compared to that of age-matched, wild-type mice [7]. The
bone weakness was indicated by lower ultimate load, smaller cross-sectional area, and
thinner cortices. In contrast, Montgomery et al. found that 16-week old mdx mice had
stronger, wider and denser femurs compared to those from wild-type mice [84]. In this
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latter study, after adjusting for the greater body weight of mdx mice, no differences in
bone characteristics were detected between mdx and wild-type mice. Thus, it remains to
be determined whether or not mdx bones are functionally compromised as a secondary
consequence of the muscle disease.
DXA, X-ray, and histomorphometry are traditional methods used to analyze bone
and were used in the two aforementioned studies. A newer and more sensitive technique
is micro-computed tomography (µCT), which simultaneously quantifies bone volumetric
density and geometry at a higher resolution providing more sensitive assessment of bone.
Furthermore, µCT is a non-destructive imaging technique that allows for subsequent
evaluations of the bones composition and functional properties to be performed on
the same specimen. Collectively, these approaches can be utilized to investigate bone
strength and elucidate the mechanisms underlying a loss in bone strength that occur
as a result of muscular dystrophy. This information may provide insight for designing
strategies that could be used to offset the deleterious effects of the disease on bone.
Therefore, the primary objective of our study was to determine if mdx mice indeed
have compromised bone compared to wild-type mice, and if so, what geometric and
material properties contribute. Specifically, three-point bending tests, µCT imaging
and measurements of bone composition were utilized to assess bone strength, geometry
and intrinsic material properties of the tibia, respectively. We also used these strategies
to assess bone in a second model of DMD, dko mice. Dko mice lack functional dystrophin
and utrophin proteins resulting in a more severe phenotype of the disease relative to
mdx mice [86]; this phenotype is more similar to that seen in boys with DMD.
Another objective of the study was to directly evaluate the functional relationships
between muscle and bone in this mouse model of muscle disease. Previous studies have
suggested that skeletal muscle not only provides an anabolic stimulus to bone but is
also required to maintain the structural competence of bone [87]. Thus, according to
the mechanostat theory [22], the loss of muscle function with DMD disease progression
should translate to proportional declines in tibial bone size and strength. To address this
theory, we calculated bone-to-muscle ratios of functional capacity using our measure-
ments of ultimate load and stiffness for the tibial bone and force generating capacities
for the extensor digitorum longus (EDL) muscle. We hypothesized that dystrophic mice
would exhibit similar bone-to-muscle ratios as those of wild-type mice, indicating that
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their tibial bone function is diminished to a similar extent as the contractile function of
the adjacent EDL muscle.
3.3 Methods
3.3.1 Animals and Experimental Design
Four wk-old wild-type (C57BL/10) and mdx mice (n=8 and 7, respectively) in addition
to 8-mo-old wild-type and mdx retired breeders (n=9 each) were obtained from Jackson
Laboratories (Bar Harbor, ME). Four wk-old dko mice (n=7) were obtained from our
colony [88]. All wild-type and mdx mice were male; dko mice were male and female (n=4
and 3, respectively). Female dko mice were included due to the limited availability of
male dko mice. Mice were housed in groups of four on a 12:12-h light-dark cycle at 20-23
oC under pathogen-free conditions. All mice were provided food and water ad libitum.
All procedures were approved by the Institutional Animal Care and Use Committee at
the University of Minnesota.
At the age of 7 wk or 24 mo, mice were weighed, anesthetized with sodium pen-
tobarbital (100 mg/kg i.p.), and EDL muscles were dissected for contractile analyses.
Mice were then sacrificed with an overdose of sodium pentobarbital (200 mg/kg) and
tibial bones were excised. These bones were stored in phosphate-buffered saline at -20
oC until the time of analysis. The 7 wk age was chosen because it was thought to
best reflect a time point with functional declines in both muscle and bone. Additional
rationale for selecting the 7 wk time point was that it approximates the average lifespan
of dko mice in our colony. Despite a report that the average lifespan of male mdx mice
is 21.5 mo [84], all of our mdx retired breeders lived to 24 mo and remained apparently
healthy. Therefore the 24-mo-old mdx mice in this study were mice that had lived with
a chronic muscle disease.
3.3.2 Contractility of EDL Muscle
EDL muscle contractile function was measured as previously described [89, 90]. Briefly,
the muscle was placed in a 0.38-ml bath assembly filled with KrebsRinger bicarbonate
buffer that was maintained at 25 oC; the proximal tendon was connected with 6-0 suture
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to the arm of a dual-mode muscle lever system (300B-LR; Aurora Scientific Inc., Aurora,
ON, Canada). Optimal muscle length (Lo) was set and then maximal isometric tetanic
force was determined by stimulating muscles with 0.5-ms pulses at 180 Hz and 150 V
for 400 ms (Grass S48 stimulator connected to a SIU5D stimulus isolation unit; Grass
Telefactor, Warwick, RI). The maximal isometric tetanic force was then normalized to
the EDL muscles physiological cross-sectional area (i.e. muscle mass divided by the
product of muscle density (1.06 g/ml) and fiber length (0.44.Lo)) [91]. Peak eccentric
force was determined by passively shortening the muscle from Lo to 0.95 Lo, and then
simultaneously stimulating the muscle for 133 ms as the muscle lengthened to 1.05 Lo
at 0.75 Lo/s.
3.3.3 µCT of Tibial Mid-Diaphysis and Metaphysis
A µCT system (Scanco Medical µCT 40, Brttisellen, Switzerland) was used to quantify
cortical bone geometry and volumetric bone mineral density (vBMD) of the tibia at
the mid-diaphysis; trabecular morphometry in the tibial metaphysis was also assessed.
The scanner was set to a voltage of 55 kVp and a current of 145 µA, and bones were
scanned using an isotropic 12 µm voxel size with a 250 ms integration time. At the
mid-diaphysis, 66 sequential two-dimensional grayscale slices (12 µm thickness) were
obtained, as previously described [12]. After image segmentation for bone using a
global threshold, an algorithm was used to compute the following morphometric outcome
measures: cortical cross-sectional area, cortical thickness, periosteal diameter, cross-
sectional moment of inertia (CSMI) and vBMD. These measures were assessed for each
of the 66 slices, and then the average of the 66 slices was reported. The minimum
principal CSMI (CSMImin) was utilized in the present study as it best corresponds to
the CSMI about the bone bending axis during the three-point bending test (described
below).
Trabecular bone in the proximal tibia metaphyseal region was imaged in 50 sequen-
tial slices, beginning 5 slices distal to the last image containing the growth plate. The
mean bone volume fraction (BV/TV), trabecular number, trabecular thickness, and tra-
becular spacing were quantified to characterize bone morphometry. Upon completion of
imaging, bones were refrozen in PBS and stored at -80C until the time they underwent
mechanical testing.
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3.3.4 Three-Point Bending Tests of Tibial Mid-Diaphysis
The procedures used to assess the functional capacities of the mouse tibia have been
described in detail previously [12, 11]. Briefly, tibial length was measured with digital
calipers and the mid-diaphysis of the tibia was identified. Tibial bone functional prop-
erties were then determined by performing three-point bending at mid-diaphysis on a
Mecmesin MultiTest 1-D test machine using a Mecmesin AFG-25 load cell (Mecmesin,
West Sussex, UK). The tibia was placed onto a set of supports separated by 1 cm such
that the lateral side of the bone was placed downward. Bones were placed in this posi-
tion to provide the most stable loading position possible during the testing procedure.
Quasi-static loading was applied to the central aspect of the bone on the medial surface
using a displacement rate of 2 mm/min. The load applied to the bone was measured
by a load cell with 5 mN resolution. The load and displacement outputs were sampled
at 14 Hz by a computer and software (TestPoint version 7; Measurement Computing
Corp., Norton, MA).
The load-displacement curve for each bone (e.g., Figure 3.1A) was analyzed using
a custom-written TestPoint program [12]. The functional measures of tibial bone were
quantified by ultimate load, stiffness, and deflection and energy absorbed to ultimate
load. Ultimate load was determined by the program as the highest load obtained prior
to failure (Figure 3.1A). Once the point corresponding to ultimate load was determined
on the load-displacement curve, deflection and energy to ultimate load were determined.
For stiffness, the program searched for the highest slope along the linear portion of the
curve prior to ultimate load; the program required that the data segment contain at
least 50 data points and that the correlation between load and displacement exceed
0.99.
In addition to bone geometric properties, other extrinsic material properties for
each tibia were determined by quantifying dry and wet tibial masses. Intrinsic material
properties for each tibia were also determined using vBMD (via µCT at the tibial
midshaft and metaphysis), hydroxyproline concentration, ultimate stress and modulus of
elasticity. Wet and dry tibial masses were measured immediately prior to measurement
of the amino acid hydroxyproline, an amino acid unique to collagen. Hydroxyproline
content was assayed following the procedures of Woessner [92]. As previously described
[12], ultimate stress and modulus of elasticity were calculated for each tibial bone using
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Figure 3.1: (A) Representative load-displacement tracing obtained during a three-point
bending mechanical test on a mouse tibial bone. The components of the curve that were
analyzed for determining ultimate load, stiffness, energy to ultimate load, deflection to
ultimate load and failure load are illustrated. (B) Representative load-displacement
tracings obtained during three-point bending mechanical testing on tibial bones from
wild-type (wt), mdx, and dko mice.
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classical beam theory. Ultimate stress was calculated using the following equation:
ultimate stress = (UL.d.L)/(8.CSMI), where UL, d and L are ultimate load, medial-
lateral periosteal diameter, and bottom support span length, respectively. Modulus of
elasticity was then calculated using: modulus of elasticity = (k.L3)/(48.CSMI), where
k equals stiffness.
3.3.5 Bone and Muscle Relationships
To determine whether the tibia was more or less affected by the dystrophic condition
relative to the EDL muscles contractile strength, bone-muscle functional relationships
were examined. Tibial bones measures of functional capacity (ultimate load and stiff-
ness) were divided by the EDL muscles contractile capacity (maximum isometric and
eccentric contraction forces) as previously described [12]. These bone-to-muscle ratios
were done on a mouse-by-mouse basis, meaning that if a mouse did not have measure-
ments for both its tibial bone and EDL muscle, the ratio was not calculated. Ratios that
are higher than those for the corresponding age-matched control mice indicate that func-
tional properties of dystrophic bone are relatively greater than those of muscle, while
ratios that are lower than those for the control mice indicate the reverse.
3.3.6 Statistical Analyses
To analyze the effects of genotype (wild-type vs. mdx ) and age (7 wk vs. 24 mo),
two-way ANOVAs were utilized. When interactions were significant (p<0.05), Holm-
Sidak post hoc tests were performed to determine which combinations of conditions were
different from each other. To assess possible effects of body mass on tibial geometric
parameters at the midshaft (i.e., cortical cross sectional area, cortical wall thickness,
and periosteal diameter) as well as tibial bone wet and dry mass, two-way ANCOVAs
were run using body mass as the covariate.
To examine the effect of disease severity (i.e., the more severe dystrophin and
utrophin deficient dko mouse model relative to both dystrophin deficient mdx mice
and wild-type mice), 7 week-old dko mice were compared to wild-type and mdx mice of
the same age. Before this analysis was done, independent t-tests were performed and
percent differences were calculated to confirm that gender differences were not present
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between male and female dko mice. A one-way ANOVA was then done with genotype
as the fixed factor. If an effect of genotype was present, Holm-Sidak post-hoc measures
were used to determine differences among the genotypes. When assumptions of nor-
mality or equal variance were violated, Kruskal-Wallis One Way Analysis of Variance
on Ranks was performed along with Dunns post-hoc tests. All statistical analyses were
carried out using SigmaStat version 3.5 (Systat Software Inc; Point Richmond, CA) with
the exception of the two-way ANCOVAs which were conducted using SPSS version 12
(SPSS Inc., Chicago, IL)
3.4 Results
3.4.1 Effect of genotype on EDL muscle function
To demonstrate the severity of muscle functional impairments in the mouse models
of DMD, in vitro measures of EDL muscle contractile forces of dystrophic mice were
compared to those of wild-type mice. Mdx mice generated less maximal isometric tetanic
forces at both 7 weeks and 24 months of age (41% and 21%, respectively) compared
to their wild-type counterparts (Table 5.1). Peak eccentric force was also reduced in
mdx mice (Table 5.1). In an effort to determine the source of these decrements in EDL
muscle function in mdx mice, both the size of the EDL muscle (i.e., mass) as well as
a surrogate for muscle quality (i.e., peak isometric force normalized to muscle cross-
sectional area) were analyzed. Mdx and wild-type EDL muscle masses were equivalent
at 7 weeks of age while mdx muscles were >50% larger at 24 months (Table 5.1). Peak
isometric tetanic force normalized to muscle cross-sectional area was 20-40% less in mdx
than wild-type mice (Table 5.1). Thus, despite mdx mice having equal or greater muscle
masses, contractile function was compromised.
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Data were not statistically different between male and female dko mice for any of
the muscle or bone parameters measured (i.e., independent t-tests P ≥ 0.221) with the
greatest difference between genders being 21%. Therefore all muscle and bone results
for the two genders were collapsed into a single dko group. Comparisons of EDL muscle
from 7-week-old dko mice to those of age-matched, wild-type and mdx mice show that
dko mice have functional deficits that are even greater than those of mdx. Dko mice had
42-67% lower peak isometric and eccentric forces relative to mdx and wild-type mice
(Table 5.1). Unlike mdx mice, dko mice had decrements in both muscle size and muscle
quality (Table 5.1), confirming that dko mice have a more severe phenotype than mdx
mice in terms of muscle function.
3.4.2 Effect of genotype on tibial bone functional capacity
In general, the functional capacity of tibial bone was affected by both genotype and
age. Figure 3.1B shows exemplar load-displacement curves from wild-type, mdx and
dko tibia during the three-point bending test. Ultimate loads for tibia of mdx mice were
19 and 36% lower than those for wild-type mice at 7 weeks and 24 months, respectively
(Figure 3.2A). The larger difference in ultimate load between mdx and wild-type mice
at 24 months was attributed to an improvement with age in wild-type mice that did
not occur in mdx mice. For bone stiffness, there were both significant genotype and
age effects (Figure 3.2B). Tibial stiffness in mdx mice was 15-20% lower than wild-type
mice, indicating that mdx bone was less resistant to bending. Additional functional
properties, including energy absorbed to ultimate load and deflection to ultimate load,
also reveal that mdx tibia are compromised. Both of these properties were 36-60% lower
in 24 month-old mdx mice compared to those in 24 month-old wild-type mice (Table
3.2). Collectively, these results indicate that functional deficits are apparent in the tibial
bones of mdx mice, confirming that bone strength is compromised.
The tibia of dko mice had even lower functional capacity. For example, bone from
these mice had 34-50% lower values for ultimate load and stiffness compared to those
of mdx and wild-type mice (Figure 3.2A and B). Energy absorbed to ultimate load and
deflection to ultimate load were also smaller in dko mice than wild-type mice (61 and
17% respectively, Table 3.2), indicating that dko are less able to withstand loading.
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Figure 3.2: Effects of genotype (wild-type, mdx and dko) and age (7wk vs. 24mo) on
tibial bone (A) ultimate load and (B) stiffness. Values are mean ± SE. When significant
main effects of two-way ANOVA (p<0.05) were present, the corresponding p-values are
listed above the bars. When interactions between genotype and age were significant,
results Holm-Sidak post hoc tests (p<0.05) are indicated using the lowercase letters
above the bars; values with the same letter are not significantly different. Significant one-
way ANOVA results across the three groups of 7-wk old mice, and significant findings
from Holm-Sidak post hoc tests (p<0.05) are indicated by: * Significantly different from
wt-7wk; † Significantly different from mdx -7wk.
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3.4.3 Effect of genotype on tibial bone geometry
µCT was utilized to determine if properties reflecting bone geometry at the mid-shaft
of the tibia were affected by genotype and thus potentially could account for the differ-
ences in bone mechanical properties observed among genotypes. For CSMI at the tibial
mid-shaft, which reflects the moment of inertia during three-point bending, independent
age and genotype effects were detected. Mdx bones had CSMI values that were approx-
imately 25% lower than wild-type bones (Figure 3.3). Because cortical cross-sectional
area usually parallels CSMI, it was not surprising to find that cortical cross-sectional
area was correspondingly 6-17% smaller in mdx mice (Table 3.2). Specifically for the
24 month-old mdx mice, the smaller cross-sectional area can be largely attributed to
reduced cortical wall thickness (Table 3.2). Body mass can influence bone geometry,
therefore two-way ANCOVAs with body mass as the covariate were conducted. Results
from those analyses were similar to those presented in Table 3.2, with the exception
of periosteal diameter in which significant interactions between genotype and age were
found (p=0.002). Specifically, with body mass as a covariate, periosteal diameters were
smaller in 7-week old mdx mice (i.e., estimated marginal means for a body mass of 30.97
g was 1.25 mm vs 1.38 mm) and larger in 24 month-old mdx mice (1.26 mm vs 1.19
mm) compared to wild-type mice.
Tibial bones from 7 week old dko mice were smaller than wild-type and mdx bones for
all geometric properties at the tibial midshaft (Table 3.2 and Figure 3.2). For example
dko mice had 38-57% smaller CSMI and cross-sectional area values compared to mdx
mice, further highlighting the impact of disease severity on tibial bone. These collective
results indicate that alterations in bone geometry contribute to the compromised tibial
bone strength in dystrophic mice.
µCT was also used to determine if trabecular bone morphometry in the tibial meta-
physis was affected by genotype. For trabecular bone volume fraction (i.e., trabecular
bone volume per total volume of interest), independent genotype and age effects were
present (Table 3.2). Mdx mice had at least 27% less trabecular bone than wild-type
mice. In 7 week-old mdx mice, the reduction in bone volume fraction was largely at-
tributed to having 17% fewer trabeculae of equivalent thickness, whereas in 24 month-old
mdx mice, the number of trabeculae was not different from wild-type mice, yet the tra-
beculae were 19% thinner (Table 3.2). Consequent to these alterations in trabecular
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Figure 3.3: A) Effects of genotype (wild-type, mdx and dko) and age (7wk vs. 24mo) on
tibial bone cross sectional moment of inertia (CSMI). Values are mean ± SE. Significant
main effects of two-way ANOVA (p<0.05) and the corresponding p-values are listed
above the bars. Significant one-way ANOVA results across the three groups of 7-wk old
mice, and significant findings from Holm-Sidak post hoc tests (p<0.05) are indicated
by: * Significantly different from wt-7wk; †Significantly different from mdx -7wk. (B)
Exemplar µCT images from 7-wk old wild-type, mdx and dko mice.
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bone, the trabecular spacing was consistently 6-23% higher in mdx mice (Table 3.2).
Trabecular bone morphometry in the proximal tibial bone of 7 week-old dko mice
was different from those of wild-type and mdx mice (Table 3.2). Dko mice had 78%
lower bone volume fractions compared to wild-type mice, which was primarily due
to having 34% fewer and 22% thinner trabeculae. These data for trabecular bone
morphometry combined with the alterations seen in cortical bone geometry confirm
that bone geometry is compromised in dystrophic mice.
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3.4.4 Effect of genotype on tibial bone extrinsic and intrinsic material
properties
Extrinsic material properties of the tibia, beyond geometry, were quantified by wet and
dry tibial masses, and intrinsic material properties were quantified by vBMD, ultimate
stress, modulus of elasticity and bone hydroxyproline concentration. Tibial bone wet
and dry masses were lower in mdx mice relative to wild-type mice (Table 3.3); however
after accounting for body mass as a covariate, tibial dry mass was similar between groups
(p=0.053) . Similarly, vBMD at both the tibial mid-shaft and tibial metaphysis was
not different between the two genotypes (Table 3.3). Bone hydroxyproline concentration
(i.e., hydroxyproline content relative to dry tibial mass) revealed that the concentration
of collagen was higher in 24 month-old mdx mice compared to 24 month-old wild-type
mice (Table 3.3). While ultimate stress values were similar between mdx and wild-
type mice at 7 weeks of age, aged mdx mice had ultimate stress values that were 22%
lower than wild-type mice at 24 months of age (Table 3.3). The modulus of elasticity
within the tibial bone tended to be higher in mdx mice compared to wild-type mice (i.e.,
main effect of genotype was p=0.051) (Table 3.3). Combined, these data confirm that
compared to wild-type mice, mdx mice have smaller sized bones of similar density. With
age however, mdx mice developed higher hydroxyproline concentrations with a trend
towards higher modulus of elasticity values while ultimate stress values were diminished.
Extrinsic tibial bone material properties (i.e., wet and try tibial mass) of dko mice
were much lower compared to both mdx and wild-type mice (Table 3.3). Despite the
small bone size in dko mice, they had similar values for two of the intrinsic material
properties, i.e., trabecular vBMD, hydroxyproline concentration and ultimate stress,
compared to wild-type and mdx mice. Unlike mdx mice, dko mice had lower cortical
vBMD values and higher modulus of elasticity compared to wild-type mice. In summary
dko mice, the more severe model of DMD, have significant deficits in bone size and
cortical vBMD but their modulus of elasticity was higher than that of wild-type mice.
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3.4.5 Bone and muscle relationships
Ratios that were calculated between the functional properties of the tibia and the EDL
muscle of 7-week old mdx mice were up to 1.44 fold of those for 7-week old wild-type
mice (Figure 3.4 and Table 3.4). These data indicate that at this younger age in mdx
mice, the functional capacity of the tibial bone is relatively high compared to that of
the adjacent, diseased EDL muscle. As the mice aged to 24 months the functional
relationships between bone and muscle in mdx mice became undistinguishable from
those of wild-type mice. This observation can be attributed to two factors. First,
there were greater EDL strength gains by mdx than wild-type mice with age (i.e., EDL
muscles from 24-month mdx mice generated 47% more peak isometric force than those
from 7-week mdx mice while wild-type muscle only improved by 9% with age; Table
5.1). Second, tibia ultimate load improved with age among wild-type (i.e., by 20%)
but not mdx mice (Figure 3.2). The bone-to-muscle ratios in 7-week old dko mice were
at least 1.33 fold of those for wild-type mice of the same age, again indicating that
the functional capacity of dko tibial bone was relatively high compared to that of the
neighboring muscle (Figure 3.4 and Table 3.4)
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Figure 3.4: Effects of genotype (wild-type, mdx and dko) and age (7wk vs. 24mo) on
tibial bone to EDL muscle ratios. Values are mean ± SE. Statistically significant effects
are indicated above the bars. Significant interactions between genotype and age detected
by Holm-Sidak post hoc tests (p<0.05) are indicated by the lowercase letters above the
bars; values with the same letter are not significantly different. Significant one-way
ANOVA results across the three groups of 7-wk old mice, and significant findings from
Holm-Sidak post hoc tests (p<0.05) are indicated by: * Significantly different from
wt-7wk.
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3.5 Disscusion
We had three primary results from our study. First, mechanical testing of the tibia di-
rectly showed that tibial bones from dystrophic mice possess only 50-80% of the strength
of that from wild-type mice, illustrating that the muscle disease has downstream func-
tional effects on an associated tissue. Second, this low bone strength in dystrophic mice
was mostly attributed to altered extrinsic material properties (i.e., bone geometry and
bone mass) more so than alterations in bone mineral density or other intrinsic material
properties. Third, the functional capacity of the tibial bone of young mdx and dko mice
is greater than that of the adjacent EDL muscle as indicated by high bone-to-muscle
functional capacity ratios relative to wild-type mice, but following improvements in
muscle function in mdx mice with age the bone-to-muscle relationships in mdx mice
become equivalent to those in wild-type mice. Combined, these data highlight that
there are clear decrements in both bone and muscle tissues of dystrophic mice, as well
as a distinct relationship between muscle disease and overall bone health.
In the past decade, the necessity of muscle force application for overall bone health
has received increasing attention. Evidence from a hip prosthetic study suggested that
70% of the bending moments placed on bone originated from force produced via muscle
contractions rather than from external reaction forces [93]. As a result, it has been hy-
pothesized that muscular contractions produce the majority of mechanical load-induced
stimuli sensed by bones mechanosensory cells, which elicit adaptations in bone stiffness
and strength if warranted. Several prospective studies have provided indirect evidence
in favor of this hypothesis, by showing that bone loss followed muscle atrophy and
conversely, that bone was regained after muscle mass recovered [41, 40].
In muscular degenerative diseases that are progressive such as DMD, declines in
bone strength and stiffness should theoretically follow decrements in muscle function
(i.e., the magnitude and frequency of force production). This reduction in muscle load
placed on bone in DMD is the combined effects of loss of contractile strength [49, 94]
and the progressive inability to perform activities of daily living [53, 52, 44]. In line with
this, recent clinical evidence has shown that boys with DMD lose the greatest amount of
bone following the loss of ambulation [2, 55]. While this loss of bone mass is expected to
be appropriate for the loss of muscle function, it likely increases the bones propensity to
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fracture. This highlights the necessity of muscle-induced loading for proper maintenance
of the skeleton in effort to prevent fractures. The present study, consistent with previous
work in mdx and dko mice [86, 49], confirmed that dystrophic muscle generated 20-60%
lower levels of force compared to that from wild-type mice. This reduction in force
generating capacity in 24 month-old mdx mice may appear surprising due to their
larger sized EDL muscles; however we are not the first to report this. Between the ages
of 6 to 28 months, Lynch et al. [49] has shown that mdx mice have larger sized EDL
and soleus muscles compared to wild-type mice, which is likely attributed to a lifelong
accumulation of fibrosis within the muscle. The greatest deficits in muscle function we
found were found in dko mice, which have been shown to have a more severe phenotype
(i.e., lacking both dystrophin and its homolog utrophin) suggesting to better mimic
muscle deterioration in boys with DMD. Likewise, we predicted and our data support
that tibia from mdx mice were functionally compromised and those from dko mice were
worse yet.
Our findings confirm and extend the work of Anderson et al. [7], showing that tibial
bones from dystrophic mice are indeed functionally weakened. Specifically, we found
that the tibial bone from mdx and dko mice were up to 50% lower for ultimate loads
and 44% lower for stiffness than those of wild-type mice. These results are in parallel
with the mechanostat theory, that is, one would have predicted that the progressive
reductions in the magnitude and frequency of mechanical loading of dystrophic mice (i.e.
weakened muscle contractions and reduced physical activity levels [88]) would translate
to lower bone strength and stiffness compared to non-diseased mice. Contrary to the
mechanostat theory, our bone-to-muscle ratios were not equivalent across genotypes
in young mice, suggesting that the functional capacities of bone and muscle were not
appropriately matched. Specifically, young dystrophic mice had up to 50% higher ratios
compared to wild-type mice, implying that the tibial bone of these young mice was
over-adapted relative to the function of the diseased muscle. Adaptations in bone are
known to lag those of muscle, and because we selected the 7-week time point, mdx
muscle had reached its peak rate of muscle deterioration (i.e., 3-4 weeks after weaning
[95]); however, appropriate alterations to bone function had likely only been initiated.
Alternatively, it is plausible that the lack of dystrophin caused a subtle prenatal bone
effect that was apparent in the young, 7-week old mdx mice, but had resolved in the
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older mdx mice. This is speculation because how bone develops during the first three
weeks of life in dystrophic mice has not been investigated. By 24 months of age, mdx
mice muscle strength had increased by 45% while their bone strength had remained
unchanged, thereby resulting in bone-to-muscle ratios that were equivalent to those
of wild-type mice. This improvement in muscle function likely reversed deleterious
adaptations to bone which thereby preserved, but did not improve, its function between
7-weeks and 24-months of age. In summary, tibial bones from mdx and dko mice were
found to be functionally impaired compared to wild-type mice, which was partially
attributed to altered muscle contractile function; however, beyond the role of muscle-
induced loading, it remains necessary to investigate other contributing factors of bone
strength and function.
The skeletal factors that contribute to reductions in bone mechanical strength,
namely bone geometry and material properties of the bone, have been minimally as-
sessed in mdx mice previously [7, 8]. Our data show that dystrophic tibial bones had
smaller cortical cross-sectional area as well as reduced cortical wall thickness, both of
which presumably contribute to their compromised bone strength. More importantly
however, we found that dystrophic tibia have smaller CSMI compared to tibia from
wild-type mice. Of the aforementioned parameters, CSMI is the most important de-
terminant of a bones mechanical properties when subjected to 3-point bending. We
found CSMI to be reduced by 24-43% in dystrophic mice compared to wild-type mice.
Montgomery et al. reported that mdx mice had higher femur bone strength presumably
due to larger periosteal diameters, and equivalent cortical thickness and CSMI relative
to wild-type mice mdx [8]. However after accounting for the larger body mass in mdx
mice (i.e., performing ANCOVA with body mass as the covariate), differences between
genotypes for periosteal diameter were eliminated in that study. Because body mass
also varied among groups of mice in our study, we performed similar two-way ANCO-
VAs with body mass held as the covariate. Our results on bone geometry indicate
that muscular dystrophy independent of body mass was a detriment to bone geometry
in mdx mice. The exception was periosteal diameter in the 24 month-old mice. The
results of the two-way ANCOVA indicated that older mdx mice actually had higher
periosteal diameters after adjusting for body mass compared to wild-type mice, which
was dissimilar to the aforementioned findings of Montgomery et al.
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These somewhat contrary findings for the mdx tibia and femur may be the result
of either site-specific differences in bone geometry or due to the sensitivity of the tech-
niques utilized to quantify geometry. µCT was used in the present study, and this
technique computationally assesses bone geometry by accounting for the contribution
of each voxel and its position in bone, whereas Montgomery et al. utilized a caliper to
quantify geometry. Thus, µCT measurements provide greater sensitivity and precision
when measuring bone geometry. Further studies utilizing µCT are warranted to discern
whether regional differences in geometry exist between mdx tibia and femur. Even less
is known about geometric or material properties of bone from DMD patients. Consis-
tent with our work on dystrophic mice, preliminary results on bone geometry in boys
with DMD suggest that total cross-sectional areas are smaller than controls at various
locations along the radial and tibial length [5, 6].
In addition to altered bone geometry contributing to functionally weakened bone,
it was important to determine if the muscle disease impacted other extrinsic as well
as intrinsic material properties of bone. We found that dystrophic mice had reduced
extrinsic material properties (i.e., tibial dry and wet mass). 24-month old mdx mice
had alterations in two intrinsic material properties, i.e., hydroxyproline content and
ultimate stress, which indicated that these mice have more collagen content (i.e., less
mineralized bone tissue compared to wild-type mice) along with reduced whole bone
strength. These data are in agreement with our results of tibial bone stiffness which,
suggest that the stiffness of the tibia from 24-month old wild-type mice increases with
their declining collagen content. Based on overwhelming evidence that boys with DMD
undergo loss of areal bone mineral density [2, 1, 55, 54, 56], it may seem surprising that
tibial cortical and trabecular vBMD was not different between mdx and wild-type mice,
but this result is in agreement with findings from Montgomery et al [8]. They reported
no differences in bone mineral density at the femur or spine between mdx and wild-type
mice [8]. In addition, preliminary data from a DMD clinical trial showed that cortical
vBMD, measured near the mid-diaphysis of the forearm and tibia, was actually higher
in boys with DMD than age-matched controls, while significant deficits in vBMD were
only apparent in distal regions of these bones [5, 6]. In summary, the notion that overall
vBMD is low as a result of dystrophin deficiency should be taken cautiously since four
different bone sites of mdx mice and two bone sties of DMD patients do not show this.
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Despite the alterations in bone strength and geometry of mdx and dko tibia, a limitation
in using these animals models is that dystrophic mice do not experience fractures like
boys with DMD. A known short-coming of the mdx mouse model is that they have a
mild phenotype relative to boys with DMD both in terms of disease progression and
muscle weakness, so it is not surprising that mdx mice do not experience fractures. The
lack of clinical similarities between boys with DMD and mdx mice is attributed in part
to elevated expression of utrophin by mdx mice [96]. Dko mice on the other hand, do not
have this recovery due to the lack of utrophin, which translates to a progressive disease
including truncated growth, limited physical abilities and muscle function, development
of cardiomyopathies, and ultimately the mice suffer premature death better paralleling
boys with DMD. Dko mice also have skeletal problems, the most notable being kyphosis
of the spine [86]. Thus, utilization of the dko mouse for further bone investigations in
relation to muscular dystrophy is reasonable and will likely prove very informative.
In summary, the present study has established that dystrophic mice, mdx and dko,
do in fact have lower tibial bone strength along with deficits in muscle contractile func-
tional capacity. Our findings indicate that bone weakness was predominately the result
of adversely affected extrinsic material properties of bone (i.e., bone geometry and mass)
rather than alterations to the bones density or other intrinsic material properties. These
mouse models of DMD provide a feasible approach for future research to test therapeu-
tic regimens that ideally aim to simultaneously improve both skeletal and muscle tissues
without causing further injury to either tissue.
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4.1 Abstract
Objectives The purpose of this study was to determine the extent to which prednisolone
treatment and restricted physical activity caused deleterious changes in inherently com-
promised mdx bone. Methods Four week-old male mdx mice (n=36) were treated for
8-wk either with or without prednisolone (0.8-1.3 mg/kg/d) and were housed in tradi-
tional or small cages (restricted activity). Tibial bone strength, geometry, and intrinsic
material properties were assessed at the mid-shaft by three-point bending and micro-
computed tomography (µCT). Results Three-point bending results showed that both
prednisolone and restricted activity reduced bone strength (7%), however stiffness was
only reduced in restricted-activity mice. µCT analyses showed that cortical bone area
and cortical thickness were 13% smaller in restricted-activity mice, and may have ac-
counted for their compromised bone strength. Intrinsic material properties, including
volumetric bone mineral density (vBMD) and modulus of elasticity, were not impacted
by either treatment, however, vBMD tended to be lower in restricted-activity mice
(p=0.06). Conclusions These data show that prednisolone treatment and restricted
physical activity independently accentuate reductions in the strength and geometry of
mdx bone, but do not influence intrinsic material properties.
4.2 Introduction
Bone health is compromised secondarily to many diseases. One example of this is
Duchenne muscular dystrophy (DMD), an X chromosome-linked neuromuscular disease
that has a prevalence of 1.3 to 1.8 per 10,000 males aged 5-24 years [97]. DMD is
characterized by progressive muscle weakness that leads to physical inactivity and in-
evitably causes patients to become non-ambulatory by their early teenage years [52, 98].
Consequently, as dystrophic muscle becomes weaker, not only are there less forceful con-
tractions applying lower loads on bone, fewer muscle-induced loads to bone are applied.
As a result, bone is continually adjusting its material and geometric properties to its
current loading environment [93] and disuse-mediated bone loss can be initiated [99].
The bone loss that results may largely explain the declines in areal bone mineral density
that has been shown in boys with DMD as they age [2, 55].
Another insult to bone health is chronic usage of glucocorticoids such as prednisone,
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prednisolone and deflazacort, which are prescribed to improve muscle strength and per-
formance in DMD patients [58, 59, 100, 60]. For example, prednisone has been shown to
thwart muscle deterioration, improve physical endurance, decrease falls, improve stair
climbing, and prolong independent ambulation in patients with DMD [58, 59, 100, 60].
In parallel with these benefits to muscle tissue, glucocorticoids induce osteoporosis and
increase fracture risk by increasing osteocyte and osteoblast apoptosis as well as extend-
ing the lifespan of osteoclasts [63, 61, 62]. Specific to DMD, the use of glucocorticoids
has been shown to accentuate reductions in bone mass and density [1, 64, 55], increase
the incidence of long bone fractures by nearly three-fold [64], and provoke the emergence
of vertebral compression fractures which do not occur in patients with DMD whom are
not treated with glucocorticoids [65, 64]. These results suggest that altered osteoblast
and osteoclast viability disrupt the homeostasis of bone remodeling and therefore may
translate to compromised bone structure and strength. Considering that bone is in-
herently compromised in strength and has altered geometry in individuals with DMD
[7, 4, 5, 6, 8, 66, 13], the addition of reduced physical activity and the use of a gluco-
corticoid may cause further decrements to the structural and material integrity of bone,
but contributions of these combined insults have not been thoroughly investigated.
The mdx mouse is an animal model of DMD that can be utilized to investigate
the musculoskeletal system because the mice display muscle weakness [101], reduced
physical activities [88], and compromised bone structure and function compared to
wildtype mice [8, 66, 13]. The deficits in muscle function and physical activity in
mdx mice are less severe relative to patients with DMD and theoretically would have
lesser impacts on bone loading. Therefore, an additional intervention was utilized in
the current study to amplify reductions in mechanical loading of hindlimb bone in
mdx mice. Traditional approaches for reducing mechanical loading in rodent models
include denervation, hindlimb suspension and casting [102, 103]. These models however,
drastically disrupt the ability of mice to ambulate, and therefore would not appropriately
model reductions in physical activity in DMD patients. We used the approach of housing
mdx mice in cages that were 80% smaller in volume than typical mouse cages to restrict
physical activities while still permitting the mice some movement. We theorized that
this approach would better mimic boys with DMD who are physically inactive yet
retained some ambulation, standing, and activities of daily living.
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Quantifying the functional capacity of bone is a good predictor of fracture risk. This
requires ex vivo analyses of bone and thus is not possible to directly study in boys with
DMD following glucocorticoid treatment and in response to reduced physical activity.
Therefore, the primary objective of this study was to use the mdx mouse model of
DMD to determine the extent to which a glucocorticoid and restricted physical activity
alter the functional capacity of the tibia as well as determine if alterations in functional
capacity are explained by changes in geometric and/or intrinsic material properties.
Based on glucocorticoids resorptive effects on bone, we hypothesized that tibial bones
from prednisolone-treated mdx mice would have diminished bone strength and altered
bone geometry compared to placebo-treated mdx mice. We also sought to determine if
restrictions on cage activities (i.e., to mimic limited physical activity in boys with DMD)
exacerbated the deleterious effects of disease and prednisolone treatment on tibial bone
in mdx mice. We hypothesized that imposing restrictions on cage activity of mdx mice
would be detrimental to tibial bone functional capacity and cortical bone geometry and
further that reduced physical activity coupled with prednisolone treatment would be
the most detrimental to bone structure and function.
4.3 Methods
4.3.1 Animals
Male mdx mice aged 4 week (n=36) were purchased from Jackson Laboratories. Mice
were housed in groups of four on a 12:12 hour light-dark cycle at 20-23 oC and were
provided food and water ad libitum. At 5 weeks of age, mice were anesthetized for
pellet implantation using fentanyl citrate (10 mg/kg body weight (BW)), droperidol
(0.2 mg/kg BW) and diazepam (5 mg/kg BW). At the age of 12-13 weeks, mice were
sacrificed with an overdose of sodium pentobarbital (200 mg/kg BW). Animal care and
use procedures were approved by the Institutional Animal Care and Use Committee at
the University of Minnesota.
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4.3.2 Experimental design
At 5 weeks of age, mdx mice were randomly assigned to one of four conditions, either
without (placebo) or with prednisolone treatment and either housed in normal sized
cages (placebo: n=8; prednisolone: n=10) or small cages (i.e., placebo restricted ac-
tivity, n=8 and prednisolone restricted activity, n=10). At this same age, placebo or
prednisolone treatment was initiated and continually administered over a period of 60
days via implanted time-released pellet as previously described [90]. Mice that were
assigned to restricted activity groups were placed individually in small cages (plastic
inserts sized length x width x height: 11.8 cm x 9.0 cm x 10.7 cm) to limit horizontal
physical activities, namely ambulation.
Cage physical activity of each mouse was measured over a 24-hour period, approx-
imately 35 days after pellet implantation. At 12-13 weeks of age, mice were sacrificed
and tibial bones were excised. Bones were stored in phosphate-buffered saline at -20 oC
until the time of analysis. A subset of the physical activity data have been published
previously. Specifically, cage activity monitoring for the mdx placebo and prednisolone
groups were reported in Study 2 of Baltgalvis et al. [90]. All data pertaining to mice
with restricted activity, as well as all bone data have not been previously published.
4.3.3 Prednisolone pellet implantation and dosage
As previously described, mice were anesthetized using fentanyl citrate, droperidol and
diazepam and the pellets were implanted on the dorsal side of the neck using a trochar
[90]. The 1.5 mg, 60-day slow-release pellet (Innovative Research of America) is de-
signed to release a constant daily dosage of drug (approximately 0.8-1.3 mg/kg/day of
prednisolone). This dosage approximates the most effective dose of prednisone (0.75
mg/kg/day) prescribed to DMD patients (reviewed in [100]) and has also been shown
to improve muscle performance in mdx mice [104, 105, 106, 107, 108]. We chose to treat
mice with the glucocorticoid, prednisolone, as it eliminates the need for hepatic con-
version of prednisone into its active form prednisolone and also because deflazacort was
not available to us. Placebo pellets contained the same matrix-driven delivery system
as the prednisolone pellets, but did not contain the glucocorticoid.
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4.3.4 Physical activity monitoring
Physical activity of individual mice was monitored for 24 hours using an open-field
activity chamber and Activity Monitor software, version 5 (Med Associates Inc.) as
previously described [109]. Briefly, the chamber contains an array of infrared beams, in
which the software monitors activity counts every time an infrared beam is interrupted,
along with how long the beam is interrupted. The methods used to discern the different
types of physical activity are defined in Greising et al., and include active time, resting
time, ambulatory distance, rearing counts, and stereotypic (i.e., eating or grooming)
counts [109]. Mdx mice randomized to the restricted activity groups remained housed
in small-sized cages (11.8 cm x 9.0 cm) within the activity chamber during physical
activity monitoring, and mdx mice randomized to full activity groups had access to the
entire area of the activity chamber (27.1cm x 27.9 cm).
4.3.5 Mechanical testing of tibial mid-diaphysis
The procedures used to assess the functional capacities of the mouse tibia have been de-
scribed in detail previously [13, 11, 12]. Briefly, tibial bones were placed on their lateral
side in a Mecmesin MultiTest 1-D test machine and underwent three-point bending at
the mid-diaphysis using a Mecmesin AFG-25 load cell (Mecmesin). Functional measures
of the tibial bone were quantified by ultimate load, stiffness, and deflection and energy
absorbed to ultimate load using custom designed TestPoint software (TestPoint version
7; Measurement Computing Corp.) as previously described [13]. Upon completion of
mechanical testing, bones were refrozen in PBS and stored at -80 oC until the time
they underwent micro computed tomography (µCT) scanning. Intrinsic material prop-
erties for each tibia (i.e., ultimate stress and modulus of elasticity) were derived from
three-point bending and µCT outcome measures as previously described [13, 11, 12].
4.3.6 µCT of the tibial diaphysis
Following mechanical testing, a region near the mid-diaphysis of the tibia was scanned
with a µCT system (Scanco Medical µCT 40) to quantify cortical bone geometry and
volumetric bone density (vBMD). The µCT was set to a voltage of 55 kVp and a current
of 145 µA, and bones were scanned using an isotropic 12 µm voxel size with a 250-ms
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integration time. For diaphyseal scanning, the distal half of the tibiae was positioned
vertically in a scan tube and its length measured on the scout view image. Start position
was set at 85% of the total length in the proximal direction from the distal-most point of
the tibia (i.e., slightly distal to where the bone broke during three-point bending), and
66 slices (∼0.8 mm) distal to this point were scanned. Outcome measures for cortical
bone at the tibial diaphysis include cortical bone cross-sectional area, cortical thickness,
periosteal diameter, cross-sectional moment of inertia (CSMI) and vBMD. Each of these
outcomes measures were assessed independently at each of the 66 slices, and the average
of all 66 slices was calculated and used for statistical analyses. As previously noted,
the minimum principal CSMI (CSMImin) was utilized in the present study due to its
correspondence with the CSMI about the bone bending axis during three-point bending
testing [13].
4.3.7 Statistical Analyses
To analyze the effects of drug (placebo vs. prednisolone) and physical activity (normal
cage size activity vs. small cage size activity), 2-way ANOVAs were utilized. When
interactions were significant (p<0.05), Holm-Sidak post-hoc tests were performed to de-
termine which combinations of conditions were different from each other. Pearson cor-
relations were also calculated between tibial bone length and other geometric properties
to provide insight into the influence of longitudinal growth on the bone cross-sectional
geometry. All statistical analyses were carried out using SigmaStat version 3.5 (Systat
Software Inc.).
4.4 Results
4.4.1 Physical activity levels and body masses
Twenty-four-hour activity monitoring was performed to confirm that housing mdx mice
in small cages decreased physical activity, thus mirroring the reductions seen in ambu-
latory distance in DMD patients. There was no effect of prednisolone on any parameter
of cage activity monitored (p≥0.154; Figure 4.1). There was also no effect of cage size
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on active time (Figure 4.1A). All groups of mdx mice spent ∼4 hours per day being ac-
tive; however, the types of activities performed during this time were different between
activity groups. Mdx mice housed in small cages ambulated 84% less distance than
traditionally housed mdx mice (76 ± 27 vs. 463 ± 27 m/24 hr, respectively; p<0.001;
Figure 4.1B), which equated to the mice in small cages spending 87 minutes less per day
ambulating. Subsequently, those restricted-activity mice spent more time grooming, as
indicated by 40% more stereotypic counts (p<0.001; Figure 4.1C).
Body masses were not different among the four groups of mdx mice at 5 weeks of age
(21.0 ± 0.2 g; p¿0.061). However at 12 weeks of age, prednisolone-treated mice weighed
4% less than placebo-treated mice (29.9 ± 0.3 vs. 31.1 ± 0.4 g, respectively; p=0.018)
and restricted-activity mice weighed 7% less than those housed in normal-sized cages
(29.3 ± 0.3 vs. 31.6 ± 0.5 g, respectfully; p<0.001).
4.4.2 Effects of prednisolone and restricted activity on tibial bone me-
chanical functional capacity
In general, the functional capacity of the tibial bone was negatively affected by both
prednisolone and restricted activity. Ultimate loads for the tibia of prednisolone-treated
and restricted activity mdx mice were low (Figure 4.2A and Table 4.1), demonstrating
that both treatments independently compromise bone strength. Restricted activity also
affected tibial bone stiffness (Figure 4.2B and Table 4.1), indicating the bones ability
to resist bending was reduced. The combination of reductions in tibial bone ultimate
load and stiffness in restricted activity mice translated to the 15% increase in deflection
to ultimate load (Table 4.1). Energy absorbed to ultimate load, however, was not
impacted by either prednisolone or physical activity level (p≥0.081). Collectively, these
results indicate that restrictions on physical activity cause further decrements in the
functional capacities of the mdx tibial bone compared to disease progression alone,
while prednisolone appears to negatively impact only the bones bending strength.
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Figure 4.1: Effects of prednisolone and restricted activity on 24-hour physical activity
measures including (A) active time, (B) ambulatory distance and (C) stereotypic counts.
Values are mean ± SE. Data are normalized to the values of placebo-treated mdx mice
housed in normal-sized cages that permitted full activity. Restricted Activity refers to
mdx mice housed in 80% smaller cage by volume. Significant main effects of two-way
ANOVA (p<0.05) are indicated above the bars.
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Figure 4.2: Effects of prednisolone and restricted activity on tibial bone (A) ultimate
load and (B) stiffness. Values are mean ± SE. Data are normalized to the values of
placebo-treated mdx mice housed in normal-sized cages to permit full activity. Re-
stricted Activity refers to mdx mice housed in 80% smaller cage by volume. Significant
main effects of two-way ANOVA (p<0.05) are indicated above the bars.
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4.4.3 Effects of prednisolone and restricted activity on tibial bone ge-
ometry
µCT was utilized to determine if tibial bone geometry near the mid-shaft was impacted
by prednisolone or restricted activity, which may have contributed to the alterations in
mechanical functional capacity. For prednisolone-treated mdx mice, the area of the cor-
tical bone was 8% smaller, which resulted from 6% smaller cortical thickness(Table 4.1).
These deficits likely contributed to the reduction in ultimate load seen in prednisolone-
treated mice. Additional measures of cortical bone geometry, including periosteal diame-
ter and CSMI, were not affected by prednisolone treatment (p¿0.26). Restricted activity
consistently showed a detrimental influence on bone geometry. Specifically, mdx mice
that were restricted had 13% smaller cortical cross-sectional area, 13% smaller cortical
thickness and 3% smaller periosteal diameter, and 17% lower CSMI (i.e., reflection of
the moment of inertia during three-point bending), compared to mdx mice with non-
restricted activity (Table 4.1). Tibial bone length (Table 4.1), however was positively
correlated with cortical cross-sectional area, cortical thickness and CSMI (r= 0.37 to
0.48; p<0.03) but not periosteal diameter (p=0.21). Combined, these reductions in
cortical bone geometry in mdx mice with restricted activity indicate that reductions in
physical activity resulted in smaller sized tibial bones and thus may have contributed
to the differences in tibial bone mechanical properties.
4.4.4 Effects of prednisolone and restricted activity on tibial bone in-
trinsic material properties
Intrinsic material properties of the tibia were quantified by ultimate stress, modulus of
elasticity and vBMD. Ultimate stress values were 15% higher in placebo-treated mice
with restricted activity compared to placebo mice (i.e., significant interaction; Table
4.1). The combination of prednisolone and restricted activity blunted this increase, such
that ultimate stress values were similar to placebo mice but 8% lower than restricted-
activity placebo mice (Table 4.1). Differences among groups were not apparent for
modulus of elasticity and vBMD, although vBMD tended to be lower in restricted
activity mice (i.e., p=0.06 main effect of activity).
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4.5 Discussion
We had two primary findings from our study. First, mechanical testing of tibial bones
from mdx mice showed that both prednisolone treatment and restricted physical activity
independently reduced the ultimate load (Figure 4.2A and Table 4.1). Secondly, reduc-
tions in tibial bone strength and stiffness were primarily attributed to having smaller
bone geometry at the tibial midshaft, rather than alterations in the intrinsic material
properties, such as vBMD (Table 4.1). Combined, these data indicate that prednisolone
treatment and restricted physical activity independently augment the deleterious effects
associated with DMD disease progression on the bones functional capacity and geome-
try, and may therefore further predispose bone to fracture.
Our previous work confirmed that mdx mice have inherently weak tibial bones (e.g.,
20-50% lower ultimate loads) relative to wildtype mice [13], and the present study
extends these findings using clinically-relevant conditions. Specifically, prednisolone
treatment and restricted physical activity each resulted in a 7% reduction in ultimate
load (Figure 4.2A). Similar 9% declines in bone strength have been realized in rats after
8 weeks of prednisone treatment [110]; however up to 50% reductions in mouse femur
bone strength have been realized with high doses of prednisone (i.e., 1.4 mg/kg/day)
[111]. Additional evidence implicating glucocorticoids role in altering bone strength
arises from the occurrence of vertebral compression fractures that are present in DMD
patients only after taking prednisone in excess of three years [65, 64]. Compression
tests performed on vertebrae have confirmed these clinical observations suggesting bone
strength is indeed compromised following the use of glucocorticoids such as prednisone
[112, 61, 113]. Combined, these data highlight the deleterious effect of this class of
drugs on the strength of various bones. The declines in mechanical function following
restricted physical activity are in accordance with other forms of severe immobilization
(i.e., denervation, fixation, or hindlimb suspension), in which bone strength is reduced
10-20% [102, 103]. Reductions in tibial bone stiffness, however, were only apparent
in mice with restricted activity (-11%, Figure 4.2B), highlighting the importance of
dynamic loading (e.g. ambulation) rather than static loads (i.e., grooming) for the
preservation of bones mechanical strength and stiffness in dystrophic mice.
The mechanical strength of bone is largely dependent upon the geometry, or shape,
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of the bone as well as its material properties. Therefore, to determine the extent to
which cortical bone geometry was affected by prednisolone treatment and restricted ac-
tivity, µCT was performed. Our present work confirms previous studies suggesting that
glucocorticoid treatment and reduced physical activity have the capacity to negatively
alter bone geometry [114, 64, 115], as well as expands our previous work showing that
the bone of dystrophic mice has altered bone geometry [13]. Specifically, prednisolone
treatment and restricted physical activity independently caused up to 12% further decre-
ments in tibial bones cortical cross-sectional area and cortical thickness compared to
disease progression alone (Table 4.1). These data are in agreement with preliminary
pQCT findings in boys with DMD, which suggest that cross-sectional areas of the tibia
and radius are reduced, and following the loss of ambulation, the areas become further
reduced [4, 5, 6]. CSMI, which is the most precise determinant of bones mechanical
properties during three-point bending, was not affected by prednisolone treatment, but
was lower in mdx mice with restricted activity (Table 4.1). Preliminary pQCT data
show that boys with DMD have 32% lower strength-strain index (i.e., a pQCT-derived
surrogate for polar CSMI) compared to healthy boys [4, 5, 6]. Further, those findings
suggest that differences were accentuated in non-ambulatory boys, but congruent with
the present study, were not influenced by the use of glucocorticoid. It is possible that
in our study differences in the rates of longitudinal bone growth among groups of mice
may partially or totally account for the observed differences in bone cross-sectional
geometry. To probe this idea, we calculated correlations and found that cortical cross-
sectional area, cortical thickness and CSMI (but not periosteal diameter) were modestly
correlated with tibial bone length. Despite these positive associations, the among-group
statistical comparison findings for cortical cross-sectional area and CSMI do not match
those for tibial bone length (Table 4.1), suggesting that differential longitudinal bone
growth rates do not completely explain the differences among groups in bone cross-
sectional geometry. Combined, these results indicate that glucocorticoids and restricted
physical activity both have deleterious effects on bone cross-sectional area; however,
physical activity alone has a negative impact on CSMI.
Beyond investigating the role of prednisolone and restricted activitys capacity to
alter bone geometry, we also investigated the impact that these factors have on the
tibial bones intrinsic material properties. Neither modulus of elasticity nor vBMD were
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impacted by prednisolone use or restricted activity; however, there was a trend toward
mdx mice with restricted activity having lower vBMD (p=0.06, Table 4.1). Declines in
bone mass following reductions in physical activity [116, 37], as well as with DMD disease
progression [56, 2, 117] have been well documented. In the present study, the effect of
restricted activity on tibia vBMD may have been minimized because mice engaged in
some weight-bearing activities that loaded the hindlimb bones (i.e., rearing while doing
stereotypic activities), which may have blunted loss of bone mass. Preliminary pQCT
studies in boys with DMD show that vBMD is not affected by prednisone use [4] and
cortical vBMD at the mid-diaphysis may actually be higher than age-matched controls
[5, 6], suggesting that bones intrinsic material properties are also minimally affected by
glucocorticoids.
In summary, the present study has established that prednisolone treatment and re-
strictions on physical activity negatively and independently accentuate reductions in
the strength of cortical bone of mdx mice. Tibia from mice that were treated with pred-
nisolone and were restricted in their physical activity had the lowest values of function
and structure (e.g., ultimate load, cortical bone cross-sectional area, and cortical thick-
ness). The reductions in bone strength are attributed to alterations in bone geometry
rather than altered intrinsic material properties. These results indicate prednisolone
and restrictions of physical activity have detrimental affects on skeletal health, and may
possibly contribute to the development of bone fragility and heightened fracture risk in
boys with DMD.
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5.1 Abstract
Objectives: This study aimed to identify parameters of low intensity vibration that
initiated the greatest osteogenic response in dystrophin-deficient mice and confirm that
vibration is not deleterious to diseased skeletal muscle. Methods: Mdx mice were
randomized to one of seven vibration treatments and after 14 days, plasma osteocal-
cin levels and osteogenic gene expression in tibia were compared. Muscle torque and
expression of genes associated with inflammation and myogenesis were also assessed in
hindlimb muscles. Mdx mice vibrated for 3d were compared to control mice as well as
other modalities known to elicit muscle injury, and a 7d vibration study included dys-
trophic mice with more severe phenotypes due to altered utrophin. Results: Two sets
of vibration parameters (45Hz at 0.6g and 90Hz at 0.6g) evoked an osteogenic response.
45Hz upregulated alkaline phosphatase and tended to upregulate osteoprotegerin with-
out altering RANKL levels, and 90Hz simultaneously upregulated osteprotegerin and
RANKL. Thus, subsequent muscle studies utilized the 45Hz setting. Vibration for 3 or
7d was not injurious to dystrophic muscle as shown by the lack of differences between vi-
brated and non-vibrated mice in torque production and gene expression. Conclusions:
These data indicate that vibration at 45Hz and 0.6g is safe for dystrophic muscle and
may be a potential therapeutic modality to improve musculoskeletal health in DMD.
These data indicate that vibration at 45Hz and 0.6g is safe for dystrophic muscle and
may be a potential therapeutic modality to improve musculoskeletal health in DMD.
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5.2 Introduction
Bone and muscle are biomechanically and biochemically linked at many levels. As such,
bone strength, shape, and mass are largely determined by the mechanical influences of its
associated muscles. In muscle diseases, such as Duchenne muscular dystrophy (DMD),
decrements in bone mass are apparent in various skeletal regions as a result of muscle
weakness and the consequential reductions in mechanical loading [2, 55, 6, 5]. The
loss of bone mass appears to compromise the strength of the bone, as indicated by the
prevalence of fragility fractures, which occur after falling from standing or sitting heights
[2, 3, 1, 118, 57]. The primary determinant of bone strength is shape, or geometry, and
this is altered in several skeletal regions of both patients and mouse models of DMD
[6, 5, 13, 66]. Exercise regimens such as running and jumping are typically prescribed
to improve bone strength and geometry in healthy populations, however these activities
are ill advised in patients with DMD due to their high susceptibility to fragility fractures
in bone [2, 3, 1, 57] and concern for exercise-induced muscle damage [119]. Therefore, an
alternative bone-sparing strategy is needed for DMD, one which is affective at improving
bone strength and geometry, but also safe for muscle.
Low intensity vibration (i.e., less than 1 g of acceleration, where 1 g is equivalent
to gravity) has been shown to have an anabolic effect on bone as well as prevent disuse-
mediated bone loss [81, 120, 82, 80]. However, some studies have failed to replicate
these findings when utilizing similar acceleration and frequency parameters of vibration
[121, 122, 123, 124, 125]. The conflicting results suggest that these parameters may
need to be customized to the population of interest. That is, the optimal mechanical
signal delivered by vibration to stimulate bone formation that is required to improve
geometry and strength may differ depending on the underlying status of the bone and
condition(s) that precipitated its decline.
Thus, prior to considering vibration as a bone-sparing modality for muscular dys-
trophy, our first study was designed to identify parameters of vibration that increased
circulating osteocalcin levels and initiated the greatest osteogenic response in tibia of
mdx mice. Mdx mice were selected because they have a bone phenotype similar to pa-
tients with DMD including bone strength, geometry and trabecular architecture that are
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reduced up to 78% compared to wildtype mice [13, 66, 7]. We chose circulating osteocal-
cin and specific genes along the osteoblastic lineage as well as genes associated with the
inhibition and activation of osteoclasts based on previous work [124, 126, 127, 128]. In
Study 1, we tested the hypothesis that mdx mice exposed to 14 daily bouts of low inten-
sity vibration would have increased osteogenic gene expression and elevated circulating
levels of osteocalcin compared to non-vibrated mdx mice.
After identifying the parameters of vibration that appeared to be most anabolic for
bone of mdx mice, our next objective was to assess short-term responses of dystrophic
skeletal muscle to those specific vibration-induced mechanical signals. Our previous
work on wildtype mice showed that low intensity vibration training improved muscle
contractility. Specifically, up to 20% improvements in strength and maximal rate of
relaxation occurred following 6 wk of training, with no indication of adverse effects
to muscle function [129]. However, the efficacy and impact of vibration training on
dystrophic muscle is unknown and is critical to determine because the lack of dys-
trophin renders skeletal muscle vulnerable to mechanical stress [130]. Consequently, we
performed Studies 2 and 3 to determine the extent to which low intensity vibration
impacted skeletal muscle contractility and altered the expression of genes associated
with inflammation and myogenesis. Study 2 tested the general hypothesis that three
daily bouts of vibration would not be injurious to mdx muscle. The study was designed
so that vibration-induced responses of hindlimb muscles could be directly compared
with those from muscles of mdx mice that completed 3 d of voluntary wheel running or
were subjected to a bout of injurious eccentric contractions. This was done in attempt
to place vibration training on a continuum with other physical interventions known to
elicit relatively minor and major muscle injury, that is, acute response to wheel running
[131] and eccentric contractions, respectively [130, 90]. The specific hypothesis tested in
Study 2 was that contractility and gene expression of muscles from vibrated mdx mice
would not be different than those from control mdx mice, but would be different than
those from mdx mice that wheel ran or were subjected to eccentric contraction-induced
injury.
A subsequent study tested the general hypothesis that seven daily bouts of low
intensity vibration would not be deleterious to muscle of dystrophic mice, even those
with phenotypes substantially more severe than the mdx mouse. Mice lacking both
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dystrophin and utrophin (dko mice;[86]) and mice lacking dystrophin that are haploin-
sufficient for utrophin (het ; [68, 132]) as well as mdx, were subjected to seven daily bouts
of vibration or a sham vibration intervention. The specific hypothesis tested in Study 3
was that contractility and gene expression of hindlimb muscles from vibrated dko, het,
and mdx mice would not be different than those from littermates that were subjected to
the sham vibration protocol. Support of hypotheses in Studies 2 and 3 would endorse
the premise that low intensity vibration is not harmful to dystrophic muscle and that
vibration therapy could be considered as a bone-sparing strategy in patients with DMD.
5.3 Methods
Animals
Five wk-old male mdx mice (C57Bl/10ScSn-DMDmdx) were obtained from Jackson Lab-
oratories (Bar Harbor, ME) for Study 1. For Studies 2 and 3, dystrophic mice were
obtained from our breeding colony at the University of Minnesota [133], with the ex-
ception of being backcrossed onto a pure C57Bl/10 background, which was verified by
The Jackson Laboratory. Study 2 utilized male mdx mice aged 8 wk because peak
muscle pathology occurs in the mdx mouse from about 5-10 wk of age. Study 3 utilized
3 wk-old mdx, het, and dko littermates of both sexes. Relatively younger mice were
selected for this study in order to determine the impact of vibration at the onset of
disease pathology. All mice were housed on a 12:12-h light-dark cycle at 20-23 oC and
were provided food and water ad libitum. Mice in Study 1 were killed by sodium pen-
tobarbital overdose (200 mg/kg body mass) and exsanguination. Immediately following
in vivo contractility testing, mice in Studies 2 and 3 were further anesthetized with
sodium pentobarbital (75 mg/kg body mass), muscles were dissected, and then mice
were euthanized by exsanguination. All animal care and use procedures were approved
by the Institutional Animal Care and Use Committee at the University of Minnesota.
Experimental Design
The purpose of Study 1 was to determine the parameters of vibration (i.e., acceleration
and frequency) that increased circulating osteocalcin levels and initiated the greatest
osteogenic response in tibia of mdx mice. To do this, mdx mice were randomly assigned
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to one of seven vibration treatments; non-vibrated control (n=8), 30 Hz at 0.3 g (n=6),
30 Hz at 0.6 g (n=6), 45 Hz at 0.3 g (n=8), 45 Hz at 0.6 g (n=8), 90 Hz at 0.3 g (n=6),
or 90 Hz at 0.6 g (n=6). At 6 wk of age, mdx mice began daily bouts of vibration (7
d/wk for 15 min/d) for 14 d. For this and all subsequent studies, non-vibrated control
mice (i.e., 0 Hz at 0 g) were placed on a vibration platform while the system was turned
off. Approximately 1 hr following the last bout of vibration, mice were anesthetized and
plasma was collected via cardiac puncture to assess the impact vibration training had
on a circulating marker of bone formation. Tibial bones were removed, flash frozen in
liquid nitrogen, and then stored at -80 C until the time of RNA isolation.
The purpose of Study 2 was to determine if vibration was injurious to mdx muscle
by placing it along a continuum with other physical interventions that are known to
elicit minimal or major muscle injury in mice (i.e., acute wheel running and eccentric
contractions, respectfully). To do this, mdx mice were randomly assigned to one of
four groups; control (n=10), vibration (n=11), wheel running (n=8), or eccentric con-
tractions (n=8). Cage activities were also monitored in control, vibration and wheel
running groups to determine whether vibration was stressful to mdx mice [134]. Follow-
ing the third daily bout of vibration (15 min/d, using 45 Hz and 0.6 g), 3 d of voluntary
wheel running, or 3 d after a single bout of injurious eccentric contractions, plasma was
collected from the retro-orbital cavity to assess creatine kinase (CK) activity and stored
at -80 oC. Contractility of the posterior crural muscle group (gastrocnemius, plantaris,
soleus muscles) was then tested in vivo. Immediately following contractility testing,
gastrocnemius muscles were excised, flash frozen in liquid nitrogen, and stored at -80
oC. Subsequently, these muscles were used to determine the relative potential of low
intensity vibration to increase expression of genes associated with muscle inflammation
and myogenesis.
The purpose of Study 3 was to extend the evaluation of short-term responses of dys-
trophic muscle to vibration by lengthening the duration of vibration exposure to 7 d and
by using dystrophic mouse models that have more severe phenotypes than mdx mice.
To do this, mdx, het and dko mice were randomly assigned to vibration training (n=
8, 8 and 7, respectfully) or non-vibrated control groups (n= 9, 12 and 7, respectfully)
at 3 wk of age. Twenty-four hours after the seventh bout of vibration (15 min/d at
45 Hz and 0.6 g), plasma was collected from the retro-orbital cavity to assess CK, and
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then posterior crural muscle contractility was assessed in vivo. Immediately following
testing, tibialis anterior (TA) muscles were excised, flash frozen in liquid nitrogen, and
stored at -80 oC until RNA was isolated to assess gene expression.
Vibration Training
Our low intensity vibration device was designed after the work of Fritton et al. [135] with
minor modifications that improve device performance and ensure fidelity [173]. Briefly,
the circular vibration platform is driven by a centrally-mounted linear actuator (Moog
CSA Engineering, Mountain View, CA) on the underside of the platform. A custom-
designed program created with LabVIEW software (National Instruments, Austin, TX)
controls and modulates the linear actuator based on continual accelerometer feedback.
Mice were placed into one of four individual compartments of the centrally-mounted
cage (See Figure 5.1 of [173]). The height of the cage was set to 5 cm to limit rearing
and jumping by the mice.
Wheel Running
Mice were individually housed in cages containing running wheels (Single Activity Wheel
Chambers, Model 80820, Lafayette Instruments Co., Lafayette, IL). One gram of resis-
tance was applied to each wheel using resistance brakes (Model 86070-B1, Lafayette
Instruments). Total distance run over the 3-d study was measured using the manufac-
turers software (Model 86065, Lafayette Instruments).This 72-hr of distance recording
excluded the 30 min during which cage activity was monitored.
Eccentric Contractions
In effort to compare vibration training to a relatively major muscle injury intervention,
the posterior crural muscles of anesthetized mdx mice underwent a series of 100 eccen-
tric contractions as previously described [136].
Cage Activity Monitoring
As a means of determining if vibration was stressful, as shown to occur with mild exer-
cise in mdx mice [137], cage activities were monitored in vibrated mice and compared
to non-vibrated control and wheel-running mice. Cage activity was not measured in the
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mice that performed the eccentric contractions because of the lingering effects of anes-
thesia. Active time, ambulatory distance, and stereotypic time (i.e., eating or grooming)
were measured for 30 min immediately after a bout of vibration (Med Associates Inc.,
St. Albans, VT) [109].
Plasma Osteocalcin and CK Activity
Circulating levels of osteocalcin were assessed in plasma using an ELISA assay (Biomed-
ical Technologies Inc., Stoughton, MA). The assay was performed in duplicate using 1:10
dilution of plasma and following manufacturer specifications. Data for the standards
were fit using a 4-parameter logistic curve fit.
Plasma CK activity was determined in duplicate with plasma diluted 1:2 in PBS.
Activity was measured using a kinetic assay (Creatine Kinase, C7512-300, Pointe Sci-
entific, Inc., Canton, MI) and a Spectramax Plus 384 spectrophotometer with Softmax
Pro v5 (Molecular Devices, Sunnyvale, CA) [138].
In vivo Posterior Crural Muscle Function
Contractile function of the posterior crural muscles was tested as previously reported
[139]. After severing the peroneal nerve, the sciatic nerve was stimulated at 250 Hz
for 150 ms to elicit maximal isometric torque. Torque production as a function of
stimulation frequency was measured as described previously [133], with the addition of
measurements at 200 and 250 Hz.
RNA Isolation and Real-Time RT-PCR
RNA was isolated from the left tibial bones of mice in Study 1 by homogenizing in
liquid nitrogen using a mortar and pestle and then transferring the powdered bone to
TRI reagent (Applied Biosystems, Austin, TX). Phases were separated by centrifuga-
tion and RNA was precipitated by ethanol addition and then applied to RNA clean-up
spin columns (Qiagen, Valencia, CA). DNA contaminates were removed by RNase-Free
DNase treatment (Promega, Madison, WI) and total RNA concentration was quanti-
fied on a Nanodrop spectrophotometer (Nanodrop, Wilmington, DE). One microgram
of cDNA was then diluted, synthesized and reverse transcribed using High Capacity
cDNA Reverse Transcription (Applied Biosystems). cDNA samples were stored at -20
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oC until RT-PCR was performed. cDNA at 1:100 dilutions were then combined with
TaqMan Universal PCR Master mix (Applied Biosystems, Carlsbad, CA) and TaqMan
gene expression assays (Applied Biosystems), and were then run on a Biorad MyiQ ther-
mocycler (Hercules, CA). Genes of interest associated with osteoblast cell activation,
differentiation, signaling and bone formation included: alkaline phosphatase (ALP),
runt related transcription factor 2 (Runx2), bone morphogenetic protein 2 (BMP2),
and collagen type-1 α-1. Gene expression associated with the inhibition and activation
of osteoclasts (i.e., Osteoprotegerin (OPG) and activator for nuclear factor κB ligand
(RANKL), respectively) were also quantified.
The effects of short term vibration on gene expression associated with muscle in-
flammation (macrophage-1 antigen, (MAC-1) and the chemokine ligand 2 (MCP-1))
and myogenesis (Paired box gene-7 (Pax-7), Myogenic differentiation-1 (MyoD), and
Myogenin) were assessed in gastrocnemius and TA muscles from mice in Studies 2 and
3, respectively. RNA was isolated by homogenizing muscles in TRI reagent. One µg
of RNA was reverse transcribed and used for RT-PCR at a dilution of 1:100. For all
analyses, triplicates were run for each mouse and the average crossing threshold for each
gene of interest and the housekeeping gene (i.e., GAPDH or 18s) were used to make
comparisons against non-vibrated control mice using Rest 2009 software, described be-
low.
Statistical Analyses
To examine if vibration was stressful for dystrophic mice or altered circulating osteocal-
cin levels in Study 1, one-way ANOVAs were used to compare body mass and osteocalcin
levels across groups. To determine optimal parameters of vibration on bone in Study
1, the combined effects of acceleration (0.3 and 0.6) and frequency (30, 45 and 90 Hz)
were analyzed for tibial bone gene expression data using two-way ANOVAs (i.e., main
effects of acceleration and frequency).
For Study 2, one-way ANOVAs were used to compare body mass, plasma CK ac-
tivity, cage activities and in vivo muscle function across treatments (i.e., controls, vi-
bration, wheel running, and eccentric contractions). When assumptions of normality or
equal variance were violated, Kruskal-Wallis One Way Analysis of Variance on Ranks
was performed along with Dunns post-hoc tests. For Study 3, two-way ANOVAs were
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used to analyze the effects of treatment (non-vibrated controls vs. vibrated) and geno-
type (mdx, het and dko) on body mass, CK activity, and in vivo muscle function. For
all ANOVAs, when significant main effects or interactions were present (i.e., P<0.05),
Holm-Sidak post hoc tests were performed to determine which conditions were different
from each other. These statistical analyses were carried out using SigmaStat version
3.5 (Systat Software Inc; Point Richmond, CA).
To examine the effect of vibration on gene expression profiles compared to non-
vibrated control mice, in all studies, real time RT-PCR data were analyzed with REST
2009 Software (Qiagen). Data are expressed as relative expression compared to non-
vibrated mice with 95% confidence intervals [140]. Note that the 95% confidence in-
tervals represent data that has an exponential distribution, and therefore the data are
more heavily distributed on the lower bound making the mean closer to the lower bound
than the upper bound. As such, the length of the 95% confidence interval is smaller
below the mean than above.
5.4 Results
Study 1, Osteogenic responses: In general, vibration treatment was well tolerated
by mdx mice and did not appear to be stressful as indicated by the preservation of body
mass (25.1 ± 0.4 g in vibrated vs. 24.4 ± 0.1 g in control mice at the end of the study,
P=0.978). In addition, behavior of the mice did not appear to be affected during or
immediately after a bout of vibration.
Parameters of vibration that resulted in the greatest increase in circulating osteo-
calcin and osteogenic mRNA expression in the tibial bone in response to 14 d of 15-min
bouts of vibration were sought. However, circulating plasma osteocalcin levels were
not different among the seven groups of mice, suggesting that vibration did not alter
osteoblast activity (59.2 ± 2.2 ng/ml, P≥0.354).
Result of REST 2009 analyses revealed that osteoprotegerin mRNA expression was
significantly upregulated in mdx mice vibrated at 90 Hz and 0.6 g and modestly upregu-
lated at 45 Hz and 0.6 g (P=0.109) compared to non-vibrated mdx mice (Figure 5.1A).
RANKL mRNA expression was 1.24 fold higher at 90 Hz and 0.6 g, and equivalent to
control mdx mice at 45 Hz and 0.6 g (Figure 5.1B), suggesting that the osteoprotegerin
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to RANKL ratio is more osteogenic at 45 Hz and 0.6 g. In addition, alkaline phosphatase
mRNA expression at 45 Hz at 0.6 g was increased, but this increase was not apparent at
90 Hz at 0.6 g (Figure 5.1C). There were no detectable differences in mRNA expression
for Runx2, collagen type I-α- I, or BMP-2 at any of the six parameters of vibration
utilized compared to the non-vibrated condition (range of fold change 0.837-1.44, P≥
0.156).
Results of two-way ANOVAs showed no main effects of acceleration and frequency
(P≥0.181), with the exception of osteoprotegerin, which had a trend toward upregula-
tion at higher frequencies (P=0.052). Due to the relative elevations of alkaline phos-
phatase and osteoprotegerin mRNA expression at 45 Hz at 0.6 g those parameters were
used for subsequent muscle-specific studies in dystrophic mice.
Study 2, Contractility: To determine whether vibration was deleterious to muscle
lacking dystrophin, mdx mice were exposed to three daily bouts of vibration and then
their hindlimb muscle function was compared to control mdx mice, as well as to mdx
mice that engaged in other forms of physical activities. Specifically, mdx mice in the
wheel running group voluntarily ran 17.5 ± 2.0 km over the 3-d study and mdx mice
in the eccentric group performed 100 eccentric contractions resulting in an immediate
79% loss in eccentric torque.
Following three days of normal cage activity (i.e., controls), vibration, wheel running,
or a bout of eccentric contractions, peak isometric torque produced by the posterior
crural muscles was significantly different between groups (Figure 5.2A). Vibrated mice
were equivalent to both control and wheel running mice. As hypothesized, mdx mice
that performed eccentric contractions had up to 37% lower isometric torque values,
though post-hoc testing did not detect a significant difference between any of the groups
(Figure 5.2A). CK activity levels were different among groups (P=0.020), with eccentric
mice having 24% higher plasma CK activity levels than controls (2829.5 ± 95.2 U/L vs
2278.9 ± 122.1 U/L). There were no differences in CK activity levels between vibrated,
wheel running and control mice.
Additional measures of posterior crural muscle contractile function assessed in Study
2 including maximal rates of contraction and relaxation during isometric contractions
and isometric torque as a function of stimulation frequency confirm that vibration was
not injurious to mdx muscle (Figure 5.2). Muscles of vibrated mice generated equivalent
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Figure 5.1: Six different permutations of low-intensity vibration parameters had minimal
effects on tibial bone osteogenic mRNA expression following 14 days of daily vibration
exposure. The height of the bars indicate the fold change mRNA expression (i.e., delta-
delta CT) above non-vibrated mdx mice (represented by the horizontal gray line) and
the error bars indicate the 95% confidence intervals. *Significantly different from non-
vibrated mdx mice as determined by REST, 2009 software (P<0.05).
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torque compared to control mice and greater torque compared to eccentrically-injured
muscles at both 10 and 30 Hz (Figure 5.2B). Combined, these data indicate that muscle
contractile function was not compromised by vibration in mdx mice, as was shown with
eccentrically-injured muscle of mdx mice.
In addition, cage activity levels were not reduced during the 30 min immediately
following vibration, and in fact, these mice tended to be 7% more active than non-
vibrated controls (Figure 5.1). This increase in cage activity corresponded to ∼70
sec, and was primarily spent ambulating (11.6 ± 0.5 min in vibrated mice and 10.2 ±
0.5min in control mice, P=0.107). Despite the increase in active time, vibrated mice
traveled equivalent total distances (Figure 5.1). These results support the contention
that vibration is not detrimental to mdx mice.
Table 5.1: Comparison of 30-minute cage activity levels between mdx mice in typical
mouse cages (control), following vibration, or wheel running.
Control Vibrated
Wheel
Running
One Way
ANOVA
P-value
Active Time (min)
17.1
(0.6)
18.3
(0.4)
16.0
(0.9)
0.054
Stereotypic time (min)
10.2
(0.5)
11.6
(0.6)
9.2
(1.0)
0.111
Ambulatory distance (m)
49.3
(2.5)
55.3
(2.3)
45.8
(5.0)
0.157
Values are means (SE).
Study 3, Contractility: To further assess if vibration could be injurious to dys-
trophic mice, we extended the vibration exposure time to 7 d and utilized het and dko
mice in addition to mdx mice. These mice represent a range of dystrophic phenotypes
of DMD where dko mice in particular are very susceptible to muscle injury. Body mass
did not significantly differ among the groups following 7 d of vibration exposure (14.5
± 0.5 g, P≥0.429).
In vivo contractile testing of the posterior crural muscles showed that vibration had
no deleterious consequences on muscle function, however, by design, genotypic differ-
ences in contractile function were apparent. Peak isometric torque was not influenced
by vibration, while dko mice had up to 38% lower torque and rates of contraction and
relaxation compared to both mdx and het mice (Figure 5.3A). Similar patterns were
seen for isometric torque as a function of stimulation frequency. Vibration had no effect
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Figure 5.2: Three daily bouts of low intensity vibration on mdx mouse posterior crural
muscle contractility compared to other exercise modalities. Data are mean, SE. A: Peak
isometric torque and rates of contraction and relaxation were not detrimentally affected
by vibration. Main effect P-values from one-way ANOVA’s are indicated above each set
of bars. Despite the significant main effect for peak isometric torque, post hoc testing
did not detect a significant difference among any of the four groups. B: Isometric torque
as a function of stimulation frequency for non-vibrated control, vibrated, wheel running
and eccentrically injured mdx mice. *Significant difference determined from post hoc
testing with torque by vibrated mice greater than that by eccentric mice.
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on submaximal torques and dko mice had lower isometric torque values at all frequencies
above 80 Hz (Figure 5.3B). CK activity was measured to assess if vibration was more
injurious to models of DMD that are more susceptible to injury. There was no effect
of genotype or 7 d of vibration on plasma CK activity (1354 ± 34 U/L for all groups;
P≥0.514).
Studies 2 and 3, Gene Expression
mRNA expression profiles were assessed in two muscles to determine if early markers
of muscle inflammation and myogenesis were affected by short-term vibration training.
Vibration had no impact on any of the genes assessed in the gastrocnemius muscle fol-
lowing 3 d of exposure (P≥0.126), however, wheel running and eccentric injured muscles
had a nearly 7-fold upregulation of MAC-1 and MCP-1 mRNA expression compared to
control muscles (Figure 5.4A). Extending vibration training out to 7 d and using the
most severe model of DMD (i.e., dko mice) did not evoke changes in tibialis anterior
muscle mRNA expression levels in genes associated with muscle inflammation or myo-
genesis (Figure 5.4B, P≥0.192). Het mice, however did have a small but statistically
significant 1.4 fold increase in Pax-7 mRNA when vibrated (Figure 5.4B, P=0.044).
Combined, these data suggest that vibration is not injurious to dystrophic muscle in
terms of eliciting an inflammatory response and also showed little evidence for initiating
myogenesis.
5.5 Discussion
We had three primary findings from our project. First, low intensity vibration was well
tolerated in each of the three dystrophic mouse models utilized (i.e., mdx, het and dko
mice) and at two ages in the mdx mice. It also did not appear to be stressful based
on preservation of cage activities and body mass. Second, in response to 14 d of low
intensity vibration training, 45 Hz and 0.6 g was identified as the set of parameters that
tended to be the most osteogenic in mdx mice. As such, subsequent studies on mus-
cle responses to vibration were performed using these parameters of vibration. Third,
vibration was consistently shown to be non-injurious to dystrophic muscle of various
disease severity. Contractile function of the posterior crural muscles was not different
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Figure 5.3: Seven daily bouts of low intensity vibration training on posterior crural
muscle contractility in three mouse models of DMD which vary in their disease severity.
Data are mean, SE. A: Peak isometric torque and rates of contraction and relaxation
were not different between control and vibrated mice. Dko mice consistently had lower
contractility than both mdx and het mice. Main effect P-values from two-way ANOVA’s
are indicated above each set of bars with post-hoc results in words immediately below
the genotype main effects. B: Isometric torque production as a function of stimulation
frequency indicated that vibration did not impact torque production at any frequency;
however dko mice had lower torque production at frequencies above 80 Hz. Only main
effects of genotype were detected, and therefore only post hoc testing results are dis-
played: *Significant difference between mdx and dko; ‡Significant difference between
het and dko.
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Figure 5.4: Low intensity vibration training for three or seven days did not affect muscle
mRNA expression of genes associated with inflammation or myogenesis. RNA was
isolated from A: gastrocnemius muscles of mdx mice three days following interventions
of vibration, wheel running, or eccentric contractions and compared to those of control
mdx mice (indicated by the solid gray line) and B: tibialis anterior muscle from mdx,
het and dko mice that were vibrated for seven days and compared to genotype-matched,
non-vibrated controls (indicated by the solid gray line). The height of the bars indicate
the fold change in mRNA expression (i.e., delta-delta CT) above controls and the error
bars indicate the 95% confidence intervals. *Significantly different from respective, non-
vibrated mdx mice as determined by REST, 2009 software (P<0.05).
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between non-vibrated and vibrated dystrophic mice, and plasma CK activity and ex-
pression levels of genes associated with muscle inflammation also were not affected by
vibration. The long term goal that this study begins to address is the potential of low
intensity vibration as a therapeutic modality for DMD. The utility of vibration has
received increasing attention in recent years due to its ability to improve musculoskele-
tal health [72, 78, 70], especially in disabled children and women with low bone mass
[81, 82, 80, 141]. Theoretically, vibration would mechanically load bone to maintain
bone health yet would be safe for the adjacent diseased muscle, and results of our study
support this theory.
Results from our first study identified two sets of vibration parameters (i.e., 90 Hz at
0.6 g and 45 Hz at 0.6 g) that evoked an osteogenic response (Figure 5.1). The 45 Hz and
0.6 g setting increased both osteoprotegerin and alkaline phosphatase mRNA levels up to
30%, but did not impact RANKL (Figure 5.1). Similar fold-change increases in alkaline
phosphatase mRNA expression have been reported following 2-4 d of a known anabolic
stimulus (i.e., four-point bending) [124, 142]. The 90 Hz and 0.6 g setting upregulated
osteoprotegerin and RANKL to similar extents, and therefore the increase in RANKL
could potentially have negated any osteoprotegerin-induced osteogenic effects. Similar
upregulation of RANKL has also been reported in mice vibrated for 21 d [126], however
in cells, vibration decreased RANKL mRNA expression up to 55% with no change in
osteoprotegerin [143]. Consistent with our findings, others have shown no change in
mRNA expression following vibration for Collagen type I [126], BMP-2 [126, 124], and
Runx-2 [124]. Consequently, our subsequent studies were performed utilizing 45 Hz
and 0.6 g because that pair of parameters tended to increase osteoprotegerin expression
with no change in RANKL and also elicited a 1.4 fold increase in of alkaline phosphatase
mRNA expression, which is involved with matrix maturation and mineralization.
The results of our second and third studies consistently showed that vibration was
not injurious to inherently fragile dystrophic muscle. The most crucial pieces of evidence
to support this statement are the functional results. That is, there was no indication
that strength (submaximal or maximal isometric torque) or contractility rates (contrac-
tion or relaxation) of the posterior crural muscles were affected by 3 or 7 of vibration
treatment in dystrophic mice. This was in contrast to other interventions, such as ec-
centric contractions, that did cause loss of strength (Figure 5.2). This was substantiated
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in the traditional mdx mouse at a younger age, as well as in more severe dystrophic
mouse models het and dko mice (Figure 5.3).
The expression profiles of genes associated with muscle inflammation and recovery
from injury further support our hypothesis that vibration is not injurious. MAC-1 and
MCP-1 are genes that meditate the recruitment and activation of inflammatory cells
following muscle damage and these genes were not upregulated after either 3 or 7 d of
vibration but were increased by wheel running or eccentric contractions (Figure 5.4).
These data indicated that vibration is on the low end of the continuum of exercises that
cause damage in dystrophic mice. Specifically, eccentrically-injured muscles had 5-7 fold
increases in MAC-1 and MCP-1 similar to previous reports [144, 145]. Interestingly, het
mice had modest increases in MAC-1 and MCP-1 following 7 d of vibration, supporting
the notion that het mice may be better models of inflammation and fibrosis in DMD
[68].
Genes associated with myogenesis were also not affected by vibration, with the
exception of upregulated Pax-7 gene following 7 d of vibration in het mice (Figure 5.4).
Vibration of cultured C2C12 myoblasts has previously shown a vibration dose-dependent
increase in MyoD and myogenin expression [146]. High intensity vibration training for
two weeks in young mice induced muscle hypertrophy that was attributed to enhanced
fusion and differentiation of satellite cells, and muscle fiber number and cross-sectional
area [147, 148]. Vibration-induced muscle hypertrophy has also been associated with
the inhibition of muscle atrophy pathways by downregulating myostatin gene expression
[149]. On the contrary, our previous work showed that eight weeks of low intensity
vibration training in wildtype mice improved muscle functional capacity in the absence
of hypertrophy [129]. Specifically, muscle strength improved by 14% but muscle mass,
protein content, and fiber cross-sectional areas were not affected [129]. Given these
improvements in the muscle function of wildtype mice, a future goal is to determine if
similar improvements are attainable in dystrophic mice and DMD patients. Reyes et
al. [141] has applied vibration directly to the elbow of children with motor disabilities
(including patients with DMD) and realized a 65% increase in muscle force compared to
a 20% decline in control patients, however the improvements in DMD patients muscle
function was not specifically stated.
The present studies thoroughly characterized dystrophic muscle function following
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short-term vibration training, after determining the vibration parameters that evoked
the greatest osteogenic response in mouse models of DMD. The results suggest that
vibration at 45 Hz and 0.6 g has the potential to have anabolic impact on bone health,
while not causing injury to inherently fragile dystrophic muscle. Additional long-term
treatment studies are needed to determine the efficacy of vibration to improve both
bone and muscle in dystrophic mice and to improve musculoskeletal health in DMD.
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6.1 Abstract
The objective of the study was to determine if low intensity, high frequency vibration
training impacted the musculoskeletal system in the mdx mouse model of DMD. Three-
week old wildtype and mdx mice were randomized to control (n=12 and 11) or vibrated
(n=14 and 11, 45Hz and 0.6g, 15min/d, 5d/wk) groups. Mdx mice were injected 5
and 1 day prior to sacrifice with Calcein and Xylenol. In vivo and ex vivo contractile
function of the anterior crural and extensor digitorum longus muscles were assessed
following 8wks of vibration and then mice were sacrificed. Muscles were prepared for
histological analyses and subcutaneous and visceral fat pads were excised and weighed.
Tibia were dissected and analyzed by micro-computed tomography for trabecular ar-
chitecture at the metaphysis and cortical geometry and density at the mid-diaphysis.
Three-point bending measured bone strength and a subset of tibia were processed for
dynamic histomorphmetry. Vibration training for 8wk did not alter trabecular architec-
ture, dynamic histomorphometry, cortical geometry, or whole bone strength (P≥0.34).
Vibration did not alter any measure of muscle contractile function in either genotype
(P≥0.12); however the preservation of muscle function and morphology in mdx mice
suggests vibration is not deleterious to muscle lacking dystrophin. Vibrated mice had
smaller subcutaneous fat pads (P=0.03) and tended to have smaller visceral fat pads
(P=0.08). These data suggest that vibration training at 45Hz and 0.6g does not signif-
icantly impact musculoskeletal function but may influence fat in mice.
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6.2 Introduction
Duchenne muscular dystrophy (DMD) is an X chromosome-linked disease characterized
by progressive muscle weakness [50, 45, 51]. Bone strength is compromised in these
patients as evident by the occurrence of fragility fractures upon falling from sitting or
standing height [2, 3, 1, 118, 57]. Compromised bone strength in DMD is multi-factorial,
likely including combined effects of the failure to accumulate peak bone strength during
growth and declines in bone health secondary to the muscle disease. Furthermore, pa-
tients are recommended to avoid moderate- to high-intensity physical activity to prevent
accelerating the muscle disease [130, 150], and consequent to the absence of exercise the
bone may fail to increase in width, also impacting bone strength. Preliminary data
suggest that bone size is reduced in various skeletal sites in boys with DMD [5, 6],
and those data are supported by reports that that these patients have low bone mass
across the lifespan [2, 55]. Paralleling suboptimal attainment of bone strength, contin-
ual declines in muscle function (i.e., the magnitude and frequency of muscle-induced
mechanical loads) likely initiate disuse-mediated bone remodeling. This is supported
by evidence that the discrepancies in bone mass between boys with DMD and their
age-matched peers are accentuated with age, especially following the loss of ambulation
where skeletal regions such as the hip and calcaneous experience drastic bone loss [2, 55].
Therefore, effective bone-sparing training modalities are warranted to thwart declines in
bone health of boys with DMD in effort to preserve bone strength and prevent fractures.
Major determinants of bone health and training modalities to preserve bone are
related to mechanical loading [76]. Bones response to mechanical loading is governed by
an inverse-frequency law, which suggests that applying low-intensity loads thousands of
times per day may be just as effective as applying few high-intensity loads per day to
maintain bone health [77].Thus in the case of DMD, where high-intensity loads (≥1500
µ) may be injurious to the inherently fragile muscle, utilizing low-intensity loads (∼5-
10 µ) more often may be a feasible approach to maintain bone health. Low intensity,
high frequency vibration applies non-invasive stimulus to bone, and is attractive as a
training modality due to evidence indicating that vibration initiates an anabolic bone
response [151], slows bone loss [72, 71], and improves bone strength [74]. Activation
patterns of postural muscles during vibration are similar to those produced during
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standing [77], and thus, the efficacy of vibration in older adults and disable children
may be attributed to the preservation of these low intensity muscle-induced stimuli. For
example, the activation of postural muscles are known to decrease three-fold with aging
[76], so vibration may be acting as a surrogate for muscle loading and stave off disuse-
mediated bone resorption. If vibration acts as a surrogate for postural muscle activation,
it may potentially explain why healthy adults do not glean beneficial effects following
chronic vibration training [152]. This suggests that vibration would be most effective
under conditions in which the magnitude and/or spectrum of mechanical loads applied
to the bone are reduced or physical inactivity is apparent. Accordingly, vibration has
been shown to be quite effective at preventing bone loss associated with bed rest [153],
as well as improving skeletal health in disabled children [82]. Consequently, vibration
may be efficacious for patients with a muscle disease, such as DMD.
The mdx mouse is a widely used model of DMD and like patients has alterations in
bone health [7, 66, 13, 154], and is relatively physically inactive [88]. Mdx mice, there-
fore, provide a feasible model to determine the efficacy of vibration to improve muscu-
loskeletal function in the presence of reduced muscle strength and physical activity. The
extent of bones response to vibration in mice is influenced by various factors including
transmissibility of the vibration stimulus, the parameters of vibration used (i.e., accel-
eration and frequency), as well as genetic background of the mice [155, 154, 156]. This
suggests that parameters of vibration are not universally effective across all mice, and
therefore, optimization may be necessary specific to the model of interest to maximize
musculoskeletal benefits. Recently, we compared six different pairs of vibration param-
eters, and identified 45 Hz at 0.6 g to best initiate an osteogenic response in mdx mice
at the mRNA level Chapter 5. It remains to be determined if those acute improvements
in gene expression at 45 Hz at 0.6 g would translate to improved bone structure and
function with prolonged vibration training in dystrophic mice.
Therefore, the objective of the present study was to determine if vibration therapy
translated to preservation of mdx mouse tibial bone trabecular architecture, cortical
geometry and whole bone strength, compared to non-vibrated mice. Previous studies in
mice have indicated that 3-6 weeks of vibration training is necessary to quantify struc-
tural adaptations within bone [127, 157, 156, 158, 159]. Consequently, we hypothesized
that 8 weeks of vibration would improve tibial bone. Specifically, three point bending
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was utilized to detect improvements in bone strength and micro-computed tomography
(µCT) was performed to elucidate the possible underlying mechanical determinants of
improved strength (i.e., geometry and intrinsic material properties). Dynamic histo-
morphometry was also used as a direct measure of osteoblastic activity in tibia from
mdx mice. In addition, we hypothesized that vibration training would not be injuri-
ous to dystrophic muscle as indicated by anterior crural muscle strength, contractility
of extensor digitorum longus (EDL) muscles, muscle morphology, and plasma creatine
kinase activity.
6.3 Methods
Animals
Three-week old male wildtype mice (C57Bl/10, n=26) and mdx mice (n=22) were ob-
tained from our breeding colony at the University of Minnesota. At 11 wk of age,
mice were anesthetized using sodium pentobarbital (37.5 mg/kg body mass (BM)), and
while under anesthesia, mice were euthanized by exsanguination. Mice were housed on
a 12:12-h light-dark cycle at 20-23 oC and were provided food and water ad libitum. All
animal care and use procedures were approved by the Institutional Animal Care and
Use Committee at the University of Minnesota.
Experimental Design
Mice were randomly assigned to either a control group (wildtype control n=12, mdx
control n=11) or vibration group (wildtype vibrated n=14, mdx vibrated n=11). Mice
allocated to the vibration groups were exposed to 15 min bouts of vibration 5 d/wk for
8 wk (range 55-58 d) starting at 3 wk of age. The vibration stimulus consisted of a 45
Hz stimulus with 0.6 g of acceleration (where 1 g is equivalent to gravity) based our
on preliminary work in mdx mice Chapter 5. Mice in the control group were placed on
the vibration platform for the same duration of time, but with the machine turned off.
Body mass was recorded weekly. To quantify dynamic trabecular bone histomorphom-
etry, mdx mice were injected subcutaneously with 15 mg/kg BM Calcein (Sigma, St.
Louis, MO) 5 days prior to sacrifice, and again one day prior to sacrifice with 90 mg/kg
BM Xylenol orange (Sigma), as adapted from [160].
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After 8 wk of vibration, mice were anesthetized for blood collection, muscle func-
tional testing, and tissue excision. Plasma was collected via retro-orbital bleed and
flash frozen in liquid nitrogen to assess creatine kinase activity. Anterior crural muscle
function was then assessed in vivo by quantifying passive and active torques and suscep-
tibility to contraction-induced injury. The EDL muscle from the contralateral limb was
then excised and used to assess ex vivo force production. The same two investigators
performed all in vivo and ex vivo measurements and they were blinded to the mouses
genotype and vibration group. Prior to exsanguination, the subcutaneous and visceral
fat pads were excised and weighed, as consistent reductions in fat pad masses have been
reported following long-term vibration training [127, 161]. The tibialis anterior, EDL,
gastrocnemius, and soleus muscles were dissected and snap frozen in liquid nitrogen or
mounted in OTC. Tibial bones were removed and stored in either phosphate-buffered
saline at -20 oC until the time of mechanical testing or in 70% alcohol at -4 oC until the
time of dynamic histomophometric processing.
µCT of Tibial Bone Metaphysis and Mid-diaphysis
A µCT system (Scanco Medical micrCT 40, Bruttisellen, Switzerland) was used to quan-
tify trabecular morphometry in the tibial metaphysis as well as cortical bone geometry
and volumetric bone density (vBMD) at the tibial mid-diaphysis [13].Trabecular bone
morphometry was assessed in the proximal tibial metaphysis (50 slice region of interest,
starting 5 slices distal to the last image containing the growth plate, using 12 um voxel
size) as previously described [13]. Bone volume fraction (BV/TV), trabecular thickness,
trabecular number, trabecular spacing and trabecular vBMD were determined for each
slice and the average value across each of the 50 slices was used for statistical analyses.
For a ∼0.8 mm region of the tibial mid-diaphysis, the following outcome measures
were assessed: cortical cross-sectional area, cortical thickness, periosteal diameter, cross-
sectional moment of inertia (CSMI), and vBMD. These measures were assessed for each
of the 66 slices within the region of interest, and the average for all 66 slices was used
for statistical analyses. Following the completion of imaging, tibial bones were refrozen
in PBS until the time they underwent mechanical testing.
Mechanical Testing of the Tibial Mid-diaphysis
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Mechanical testing procedures for assessing the functional capacity of the mouse tibial
bone has previously been described in detail [13, 12, 11]. Briefly the left tibial bone of
each mouse was placed on its lateral side in a Mecmesin MultiTest 1-D test machine,
and was loaded in three-point bending at the mid-diaphysis using a Mecmesin AFG-25
load cell (Mecmesin, West Sussex, UK). The functional capacity of the tibial bone was
quantified by ultimate load, stiffness, and deflection and energy absorbed to ultimate
load using custom designed TestPoint software (TestPoint version 7; Measurement Com-
puting Corp.) [13].
Trabecular Bone Dynamic Histomorphometry
A subset of tibia were dehydrated and embedded without demineralization in methyl-
methacrylate (Polysciences, Warrington, PA) as previously described [162]. Briefly, 5
µm thick longitudinal sections were cut on a microtome (Leica, Heidelberg, Germany)
and mounted unstained. Flurochrome labels were visualized at 20x, and dynamic his-
tomrophometric measures were made using OsteoMeasure image analyzer (OsteoMet-
ric, Atlanta, GA) in a region ∼60 µm distal to the proximal growth plate. Outcome
measures of interest include mineralized surface per bone surface (MS/BS), mineral ap-
position rate (MAR), and bone formation rates relative to bone surface or total volume
(BFR/BS and BFR/TV, respectively). All parameters were measured and expressed
according to standardized nomenclature [163]. A single investigator performed all his-
tological preparations and another investigator performed all the analyses; both were
blinded to the genotype and treatment.
In vivo Measurements of Anterior Crural Muscle Function
Mice underwent in vivo contractile testing of the anterior crural muscles of the left hind
limb while anesthetized (cocktail containing: fentanyl citrate (0.2 mg/kg BM), droperi-
dol (10 mg/kg BM), and diazepam (5 mg/kg BM)) [90]. Outcome measures of interest
included: : passive torque about the ankle [164], susceptibility to eccentric contraction-
induced injury [119] and peak-isometric torque (pre- and post-injury) [90, 165]. Torque
loss was then calculated as the difference between pre- and post-isometric torque values.
Ex Vivo Measurements of EDL Muscle Contractility
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The contractile function of EDL muscle of mdx mice was investigated as it is sensi-
tive to disease progression, contraction-induced injury, and can adapt in response to
treatment [90, 89]. Measurements included: peak twitch force, time-to-peak twitch
force, twitch one half-relaxation time, peak isometric tetanic force (Po), maximal rates
of tetanic force production and relaxation, eccentric force, and percent decline in iso-
metric tetanic force following eccentric contractions [91]. EDL muscles were trimmed,
blotted and weighed following the measurements. Physiological cross-sectional area was
calculated using EDL muscle mass, anatomical muscle length (i.e., Lo), and a fiber
length-to-muscle length ratio of 0.44, and this calculated value was used to adjust peak
isometric tetanic force to determine specific Po [91, 166].
Muscle Morphology
Altered vascularity has been noted as a possible contraindication of vibration [167],
therefore we measured capillary density at the distal end and mid-belly of the soleus
muscle using a periodic acid-Schiff reaction [168]. Capillary density was quantified by
counting the number of capillaries surrounding a fiber. Central nucleated fibers (i.e.,
a marker of muscle regeneration) were also assessed in both regions of the soleus as
well as the mid-belly of the tibialis anterior muscle. The number of central nucleated
fibers present per 300 fibers was counted in each of these regions from hematoxylin and
eosin-stained sections [88]. A single investigator performed all histological preparations
and another investigator performed all the analyses; both were blinded to the genotype
and treatment.
Statistical Analyses
The effects of vibration (45 Hz at 0.6 g vs. non-vibrated control) and genotype (wild-
type vs. mdx ) were assessed by two-way ANOVAs with vibration and genotype as the
fixed factors. When significant interactions were present, Holm-Sidak post-hoc measures
were used to determine differences among the groups. When assumptions of normality
or equal variance were violated, Kruskal-Wallis One Way Analysis of Variance on Ranks
was performed along with Dunns post-hoc measures. Dynamic histomorphometry mea-
sures of the tibia were only performed on mdx mice, and therefore the data were assessed
by t-tests. All statistical analyses were carried out using SigmaPlot version 11.0 (Systat
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Software Inc; Point Richmond, CA).
6.4 Results
Tibial Bone Trabecular Morphometry and Cortical Geometry
µCT was performed at the proximal metaphysis and mid-diaphysis of the tibia to de-
termine the extent to which vibration and genotype influenced trabecular bone mor-
phometry and cortical bone geometry, respectively. In the proximal metaphysis of the
tibia, vibration did not influence trabecular morphometry, though differences between
mdx and wildtype were detected (Figure 6.1A). Specifically, bone volume fractions,
trabecular thickness, number, and spacing did not differ between control and vibrated
mice (Figure 6.1A). The lack of improved trabecular morphometry in the metaphysis
of mdx mice following vibration was confirmed by dynamic histomorphometry (Figure
6.1B). Overall, vibration had no impact on bone formation in mdx mice as indicated by
MS/BS (34.1%, P=0.989), MAR (1.06 µm/d, P=0.373), BFR/BS (0.36 µm3/µm2/d,
P=0.633) or BFR/TV (0.193 %/d, P=0.908). For the differences in trabecular bone
morphometry across genotype, bone volume fraction showed that mdx mice had 17%
less bone than wildtype, which was attributed having 12% thinner trabeculae (Figure
6.1A). Trabecular number (Figure 6.1A) and spacing (0.185 mm +/- 0.004, P=0.559)
were not influenced by genotype.
Neither vibration nor genotype influenced any parameter of cortical geometry at the
tibial mid-shaft (Table 6.1 and Figure 6.2A). These data suggest that the shape of the
bone was similar across all groups, despite the tendency of mdx mice to have longer
tibial lengths (Table 6.1).
Tibial Bone Functional and Intrinsic Material Properties
Three point bending tests were performed at the mid-shaft of the tibial diaphysis to
determine if whole bone strength was affected, even in the absence of change in bone
geometry. The strength and stiffness of tibial bones were not different between vibrated
and non-vibrated, control mice (Figure 6.2B and C). The lack of difference was extended
to variables derived from ultimate load and stiffness including energy and deflection to
ultimate load (Table 6.1). Comparisons across genotypes confirmed that bone strength
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was compromised in mdx mice, as indicated by 9% smaller ultimate loads and a trend
toward lower tibial stiffness (Figure 6.2B and C), as well as lower energy to ultimate
load compared to wildtype mice (Table 6.1).
Mdx Control Mdx Vibrated
A
B
Figure 6.1: Effect of 8 weeks of low-intensity vibration on trabecular architecture and
dynamic histomorphometry in the proximal tibial metaphysis of mdx and wildtype mice.
A) Vibration training did not influence trabecular bone volume fractions, thickness,
spacing or number. B) Measures of dynamic histomorphometry were also not influenced
by vibration (exemplar images from two mdx mice) compared to non-vibrated mice. As
expected, mdx mice had lower values for trabecular bone volume fraction and thickness
compared to wildtype mice. Data are mean, SE. Main effect P-values from two-way
ANOVA’s are indicated above each set of bars in Panel A.
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Overall, vibration had no impact on any measure of intrinsic material properties of
the tibia (Table 6.1). While ultimate stress and modulus of elasticity values were similar
across genotypes, µCT revealed differences in vBMD between mdx and wildtype mice
at both the tibial proximal metaphysis and the cortical midshaft with mdx mice having
up to 3% lower vBMD (Table 6.1).
Anterior Crural Muscle Function
To determine if vibration training affected musculature in close proximity to the vibrat-
ing platform, passive and active torques about the ankle were assessed. Passive torque
was unaffected by vibration training at each of the nine joint angles measured (data not
shown, P≥0.087). Mdx mice had greater passive torque at 20 degrees of dorsiflexion
compared to wildtype mice but there was no difference between control and vibrated
groups (Table 6.2) suggesting that vibration did not alter muscle or joint stiffness.
Overall, the active measures of anterior crural muscle contractile function showed
no effect of vibration. Absolute and normalized maximal isometric toques were not
impacted by vibration (Table 6.2 and Figure 6.3A, respectively), indicating that muscle
strength was not altered following vibration training. Genotypic differences in isometric
torque were only apparent after accounting for increased body mass of the mdx mice
(Figure 6.3A). Susceptibility to contraction-induced injury, as indicated by declines in
eccentric torque over a series of contractions (Figure 6.3B) and isometric torque loss
(Table 6.2), were not affected by vibration. Mdx mice had a substantial loss of anterior
crural muscle function reflected by 42% lower isometric torque after the eccentric con-
tractions compared to that before (0.79 N*mm vs. 1.3 N*mm, P<0.001), and ∼70% loss
of eccentric torque (Figure 6.3B). These data indicate that lack of dystrophin but not
vibration is detrimental to muscle function. Similarly, plasma creatine kinase activity
did not differ between vibration and control groups (P=0.974), but was 4-fold higher in
mdx than wildtype mice (4507 U/L vs. 1055 U/L, P<0.001).
EDL Muscle Contractile Function
Force-generating capacity of the EDL muscle was not affected by 8 weeks of vibration
training. Vibration had no impact on peak twitch force, maximal isometric tetanic
force, specific Po, peak eccentric force, and eccentric or isometric force loss due to
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Figure 6.2: Effect of 8 weeks of low-intensity vibration on tibial bone cross-sectional
moment of inertia, ultimate load and stiffness in mdx and wildtype mice. Vibration
training did not influence tibial bone A) cross-sectional moment of inertia, B) ultimate
load, or C) stiffness compared to non-vibrated control mice. Mdx mice had lower values
for ultimate load and trends for lower stiffness compared to wildtype mice. Data are
mean, SE. Main effect P-values from two-way ANOVA’s are indicated above each set of
bars, where the P-values associated with the main effect of vibration and genotype are
listed above the bars.
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contraction-induced injury (Figure 6.4 and Table 6.2). Characteristics relating to speed
of EDL muscle contraction, including time-to-peak twitch force, half-relaxation time of
twitch force, and maximal rates of tetanic force development and relaxation were also
not effected by vibration (Table 6.2). Most of the EDL contractile measures were dif-
ferent between wildtype and mdx mice, reflecting the expected pathology of the muscle
disease (Figure 6.4 and Table 6.2).
Muscle Morphology
Tibialis anterior, soleus, and gastrocnemius muscle masses and central nucleated fibers
were not impacted by vibration (Table 6.3). Vibrated mice had 5% smaller EDL mus-
cles, primarily due to vibrated mdx mice having 9% smaller EDL muscles compared
control mdx mice (Table 6.3). Mdx mice had greater muscle masses and increased cen-
tral nucleated fibers compared to wildtype (Table 6.3).
Fat and Body Masses
At the start of the study, body mass did not differ between vibration and control groups
(P=0.654), though mdx mice weighed less than wildtype (9.0 ± 0.3 g vs 10.7 ± 0.7 g,
P=0.005). Eight weeks later mdx mice were 12% heavier than wildtype mice and vi-
brated mice tended to have reduced body mass (Figure 6.5). Vibrated mice also had
significantly smaller subcutaneous fat pads and tended to have lower visceral fat pad
masses compared to controls (Figure 6.5). Main effects of genotype were consistently
present for fat and muscle masses with mdx mice having up to 47% less fat pad masses
(Figure 6.5).
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Figure 6.3: Effect of 8 weeks of low-intensity vibration on in vivo anterior crural muscle
isometric torque and susceptibility to eccentric contraction-induced injury in mdx and
wildtype mice. A: in vivo testing of anterior crural muscle function showed that maximal
isometric torque were not different in mice subjected to vibration compared to non-
vibrated control mice. B: Vibration training did not alter susceptibility to eccentric
contraction-induced injury in vibrated mice compared to control mice. As expected,
mdx mice had lower isometric torque values and greater susceptibility to eccentric injury
(i.e., greater decrements in eccentric torque production). Data are mean, SE. Main effect
P-values from two-way ANOVA’s are indicated above each set of bars in Panel A, where
the P-values associated with the main effect of vibration and genotype are listed above
the bars. In panel B, only a main effect of genotype was present, where the * signifies
a significant difference between mdx and wildtype mice.
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Figure 6.4: Effect of 8 weeks of low-intensity vibration on Ex vivo Extensor Digitorum
Longus (EDL) muscle isometric tetanic force, specific force (Po), and susceptibility to
eccentric contraction-induced injury in mdx and wildtype mice. Vibration training did
not influence EDL muscle A) maximal isometric tetanic force production, B) Specific
force, or susceptibility to eccentric contraction-induced injury compared to non-vibrated
control mice. As expected, mdx mice had lower values for each of the thee measured
of EDL muscle function compared to wildtype mice. Data are mean, SE. Main effect
P-values from two-way ANOVA’s are indicated above each set of bars in Panel A and B,
where the P-values associated with the main effect of vibration and genotype are listed
above the bars. In panel C, only a main effect of genotype was present, where the *
signifies a significant difference between mdx and wildtype mice.
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Figure 6.5: Effect of 8 weeks of low-intensity vibration on fat pad masses and body
mass in mdx and wildtype mice. Vibrated mice had lower subcutaneous fat pads and
a trend for lower visceral fat pad masses. Mdx mice were larger in body mass, but had
lower fat pad masses compared to wildtype mice. Body masses were not different in
mice subject to vibration compared to non-vibrated control mice. Data are mean, SE.
Data were analyzed by two-way ANOVA’s and the P-values associated with the main
effects of vibration and genotype are indicated above each set of bars.
6.5 Discussion
Vibration training has been reported to enhance bone and muscle in humans and rodent
models. Our study, however, failed to show any enhancement in those tissues. First, 8
weeks of low intensity vibration training did not alter trabecular architecture, cortical
bone geometry, or whole bone strength in tibia of wildtype mice or mice with a muscle
disease. Secondly, vibration did not alter any of our measures of contractile function
of hindlimb muscles. Despite the lack of benefit, the preservation of muscle function
in mdx mice indicates that vibration is a safe training modality for dystrophic muscle.
Lastly, mice that were vibration-trained had smaller subcutaneous fat pads and tended
to have smaller visceral fat pads compared to non-vibrated mice. Combined, these data
suggest that in mice vibration training at 45 Hz and 0.6 g does not significantly impact
118
musculoskeletal function, but does affect fat pads.
Trabecular bone
We hypothesized that 8 weeks of low intensity vibration training would improve trabec-
ular architecture. Vibration training, however, did not affect any measure of trabecular
architecture or dynamic histomorphometry in the proximal tibial metaphysis (Figure
6.1 and Table 6.1). The anticipation of alterations in trabecular bone architecture was
based on several reports of improved bone health in the proximal tibia of healthy mice
following vibration training. Specifically, improvements in trabecular thickness [79, 156],
trabecular number [127], bone volume fraction [79, 127, 156], dynamic rates of bone for-
mation [79, 158], and decrease trabecular spacing [127] have been reported in response
to 3 to 6 weeks of vibration training that had used similar low intensity parameters. In
addition to these beneficial adaptations in healthy mice, vibration has also been shown
to preserve or improve trabecular bone in mice modeling disuse [120, 151], and in pa-
tients with childhood diseases [141, 82]; thus making vibration training an attractive
therapeutic modality for DMD. The lack of alterations in trabecular bone in our study
is corroborated by one other study using mdx and wildtype mice and similar parameters
of vibration [169], as well as other mouse models associated with physical inactivity and
muscle weakness [121, 125].
Cortical Bone
Reductions in mdx tibial bone strength and stiffness compared to wildtype mice (Figure
6.2) are consistent with previous reports [66, 13] and have previously been attributed to
altered bone geometry [13]. We hypothesized that 8 weeks of vibration training would
improve cortical bone geometry and whole bone strength. Cortical bone, however, was
not altered by vibration as indicated by the lack of differences in cortical bone geometry
or bone strength between vibrated and control groups (Table 6.1 and Figure 6.2). These
data are corroborated by evidence from others indicating that low intensity vibration
did not alter bone geometry at the midshaft of the tibial [157, 170] and femur [76]. Im-
provements in periosteal BFR and MAR at the tibial midshaft following vibration have
been noted, however this increase in bone growth did not translate to improvements
in cortical bone area or whole bone strength or stiffness [157]. Cortical bone dynamic
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histomorphometry was not measured in the present study due to the lack of functional
improvements in cortical bone geometry and whole bone strength.
The lack of anabolic bone response in the present study may be attributed to multi-
ple possible factors including 1) transmissibility of the vibration stimuli, 2) suboptimal
parameters of vibration, 3) the high fidelic function of our vibration platform, or 4) the
mild skeletal phenotype in mdx mice. First, bones response to vibration is dependent
upon transmissibility of the vibration stimuli, such that skeletal regions closest to the
source have more robust responses [155] compared to distal sites where transmissibil-
ity is diminished [171]. Transmission of the vibration stimuli is influenced by muscle
activation patterns and joint angles [171, 172], so it is possible that in mice a higher
intensity vibration (i.e., accelerations exceeding 1 g) would better amplify transmission
and provoke an osteogenic response as previously shown [157]. Second, the parameters of
vibration utilized in the present study may be suboptimal for long-term training. Bones
response to vibration is not universally effective and has been shown to preferentially
respond to certain vibration stimuli [13, 155, 157, 156, 158]. We previously identified
two sets of potentially osteogenic vibration parameters in mdx mice (i.e., 45 Hz and 0.6
g and 90 Hz at 0.6 g) following 14 d of vibration, based on subtle alterations in alkaline
phosphatase, osteoprotegerin and RANKL expression [13]. Bone in rats is capable of
differentiating and preferentially responding to vibration stimuli at 90 Hz rather than 45
Hz [155], thus, it is plausible that vibration using 90 Hz at 0.6 g may have initiated an
anabolic response. The third potential reason vibration didnt cause an anabolic bone
response may be due to the continually-persistent vibration stimuli produced by our
device (i.e., intra-trial and intra-animal variability was <4% at frequencies greater than
20 Hz [173]). Others who have gleaned vibration-induced anabolic responses report that
variability of their device is as high as 21% and 48% for 45 Hz and 90 Hz, respectively
[155]. Therefore, our highly-fidelic device may cause bone cells to desensitize within a
few cycles as shown with other forms of loading [174, 175]. Lastly, the mild phenotype
of mdx mice may result in insufficiently compromised bone to benefit from vibration
training, and therefore the vibration stimuli may have been redundant, rather than os-
teogenic in these mice. Vibration has been proposed to act as a surrogate for muscle
[76], as it produces bone strains equivalent to those of postural muscles during standing
[77, 74, 176]. Mdx mice, unlike DMD patients, retain the ability to independently stand
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and ambulate throughout life, and therefore, muscle-induced low level strains are likely
preserved.
Muscle Function
Eight weeks of vibration training did not alter any measure of hindlimb muscle function
(Figures 6.3 and 6.4 and Table 6.2). The overall efficacy of low intensity vibration to
improve muscle function in humans remains controversial [78, 70], with various reports
of beneficial effects [82, 141, 80, 177, 178, 153] and several reporting lack of alterations.
Few studies have used mouse models to investigate vibration and skeletal muscle and
those reports are also inconsistent in regard to effects on muscle size [125, 129, 159, 167].
The vibration training protocol used in present study did not improve muscle size or
strength in mdx or wildtype mice. The lack of vibration-induced improvements in muscle
is consistent with a more severe model of weakness and physical inactivity [125], but con-
tradicts our previous vibration work in wildtype mice in which muscle strength improved
by 10% despite no effect on muscle mass, size, or protein content [129]. Combined, these
data do not support the notion that low intensity vibration induces myogenesis.
Contraindications to muscle have been reported following vibration training [167,
179], and due to the high susceptibility of dystrophic muscle to injury, it was necessary
to establish that vibration can be a safe training modality. Our results show that 8
weeks of low intensity vibration training was not deleterious to any measure of mus-
cle function (Figures 6.3 and 6.4 and Table 6.2). The lack of injury with vibration
training corroborate our previous study in healthy mice[129], and contradicts the two
studies which have reported muscle-specific contraindication of vibration (i.e., reduced
vascularity in the distal soleus muscle in response to a low intensity vibration [167],
and centrally-located nuclei in muscle fibers following relatively high intensity vibration
[179]). Our thorough investigation utilized established recommendations for pre-clinical
testing in mdx mice including a combination of in vivo and ex vivo assessment of muscle
function providing the most comprehensive evaluation of a training modalitys efficacy
and safety [180]. We further complemented these data with histological and plasma
CK to confirm that vibration was not injurious to dystrophic muscle. As a result, our
results show that low intensity vibration is not injurious to dystrophic mouse muscle,
and therefore vibration is most likely a safe training modality for DMD.
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Fat Pads
Vibrated mice had smaller subcutaneous and visceral fat pad masses following 8 weeks
of training (Figure 6.5). These vibration-induced reduction in fat mass have been con-
sistently reported [127, 129, 161] and vibration training has even been shown to inhibit
diet-induced obesity [127]. The proposed mechanism behind these vibration-induced fat
reductions is that vibration may drive differentiation of mesenchymal stem cells away
from adipocytes toward the osteoblasts linage [127, 75, 151]. It is possible that the
continual demand for differentiation of mesenchymal stem cells in mdx mice toward
muscle precursor cells and fibroblasts may have impeded, or blunted, vibrations ability
to drive differentiation toward osteoblasts. Mdx mice in the present study indeed had
consistently smaller fat pads, independent of vibration (Figure 6.5). Stem cells in mdx
mice have also been shown to have slower proliferate rates and reduced osteogenic and
myogenic differentiation patterns [181]. Similar reductions in osteogenic gene expression
have been noted in DMD patients [154]. As a result, the failure to attain vibration-
induced osteogenic effects in mdx mice may be partially attributed to their inherently
slower and inflexible patterns of mesenchymal stem cell differentiation patterns. Despite
this possibility, wildtype mice did not respond to vibration either and mesenchymal stem
cells differentiate normally and theoretically have plasticity for altering stem cell fate in
response to vibration signals in these mice.
In summary, the present study has established that 8 weeks of low intensity vibra-
tion training at 45 Hz and 0.6 g did not significantly impact trabecular or cortical bone
within the tibia of mdx or wildtype mice. Hindlimb muscle function also was not af-
fected; however vibration may aid slowing the acquisition of fat mass. Further research
is needed to determine if alternative parameters of vibration can initiate an osteogenic
response in patients or animal models of muscle disease such as DMD.
Chapter 7
Summary Statement and Future
Directions
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The contents of this dissertation add significant findings to the fields of bone health
in muscular dystrophy and the efficacy of vibration training. Muscle strength and
physical activity are essential contributors to bone health, and decrements in these
factors have been associated with deleterious effects. The muscle disease, Duchenne
muscular dystrophy (DMD), has hallmark characteristics of progressive muscle weakness
and physical inactivity. The two most commonly used mouse models of DMD for pre-
clinical testing include the mdx and dko mice. These models are used because, similar to
patients, these mice lack functional dystrophin, display muscle weakness [101], and have
reduced physical activity levels [88]. At the start of my dissertation, only two studies
had investigated bone health in dystrophic mice, however their evidence was conflicting
[7, 8]. Therefore, the first aim of my dissertation was to confirm that skeletal health was
altered secondary to the muscle disease in mouse models of DMD and to identify the
underlying mechanisms. The second aim was to determine the extent to which physical
inactivity and a standard drug treatment for patients with DMD further impact skeletal
health. Upon establishing that bone health was altered in dystrophic mice my final
dissertation aim was to determine the safety and efficacy of an increasingly popular
intervention for bone health. Specifically, I investigated low intensity, high frequency
vibration treatment as a potential therapeutic modality to preserve, and potentially
improve, dystrophic musculoskeletal health.
My first study established that tibial bones from dystrophic mice were up to 38%
weaker in strength and stiffness compared to wildtype mice, which was attributed to
reductions in bone geometry rather than material properties (Chapter 3). Trabecular
bone health was also compromised in dystrophic mice, as indicated by up to 78% re-
duction in trabecular morphometry. Combined, the results of this study established
that dystrophic mice (i.e., mdx and dko) have an altered bone health secondary to their
muscle disease, and therefore are an appropriate model to use in pre-clinical trials for
identifying potential therapeutic regimens to improve bone health in DMD.
Upon establishing that bone health was compromised in DMD, my second study
examined the extent to which prednisolone treatment and restricted physical activity
further altered skeletal health in mdx mice. Prednisone treatment was investigated
because it is standard of care for patients with DMD due to its ability to improve muscle
strength, but it has known catabolic effects on bone. My results showed that both
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prednisolone and restricted physical activity negatively and independently accentuate
reductions in bone strength and geometry in mdx mice (Chapter 4). The combined
effects likely contribute to the development of bone fragility and a heightened fracture
risk in boys with DMD.
Due to the beneficial effects of prednisolone to thwart muscle deterioration, improve
physical endurance, and prolong independent ambulation in patients with DMD [60,
59, 58, 100], I focused my remaining studies on identifying a safe therapeutic modality
to restore physical activity levels in DMD. Low intensity vibration (i.e., less than 1 g
of acceleration, where 1 g is equivalent to gravity) has been shown to have an anabolic
effect on bone as well as prevent disuse-mediated bone loss [120, 81, 82, 80]. Several
studies, however, have failed to replicate findings [121, 122, 123, 124, 125] or have
shown differential responses [79] using similar parameters of vibration. Thus, prior to
considering vibration as a bone-sparing modality for muscular dystrophy, I attempted
to identify parameters of vibration that initiated the greatest osteogenic response in
mdx mice, yet were safe for the adjacent diseased muscle. In response to 14 d of low
intensity vibration training, two sets of parameters (i.e., 90 Hz at 0.6 g and 45 Hz at 0.6
g) were identified to be the most osteogenic based on the expression of osteoprotegerin
and alkaline phosphatase (Chapter 5). Vibration was well tolerated by dystrophic mice
and was consistently shown to be non-injurious to dystrophic muscle of various disease
severities. The results suggest that longer term vibration training at 45 Hz and 0.6 g
may have the potential to have an anabolic impact on bone health, while not causing
injury to inherently fragile dystrophic muscle.
In my final study, I investigated the efficacy of long-term low intensity vibration
training to improve dystrophic musculoskeletal health. Vibration training for 8 weeks
did not alter trabecular architecture, dynamic histomorphometry, cortical geometry,
whole bone strength, or any measure of muscle contractile function (Chapter 6). The
preservation of musculoskeletal function and histomorphometry in mdx mice suggests
vibration is not deleterious. Additionally, vibrated mice had smaller subcutaneous fat
pads and tended to have smaller visceral fat pads. Combined, these data suggest that
vibration training at 45Hz and 0.6 g does not significantly impact musculoskeletal func-
tion but may influence fat.
The lack of vibration-induced alterations in musculoskeletal health in the present
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dissertation does not completely negate the potential utility of vibration as a therapeutic
modality in DMD or other muscle diseases. It is possible that the musculoskeletal
response to vibration may have been blunted in dystrophic mice in my study due to
several factors including: 1) low transmissibility of the vibration stimuli, 2) utilization of
less than optimal parameters of vibration, and 3) the potential for rapid desensitization
of bone cells due to the consistency of the stimuli produced by my vibration device. For
example, initial work in Dr. Lowes laboratory using healthy mice vibrated at 45 Hz and
1.0 g demonstrated 14% improvements in muscle strength following 6 weeks of training
[129]. The higher acceleration of vibration used in our initial work (1.0 vs 0.6 g) may
have improved the transmissibility of the vibration stimuli and therefore the response of
the muscle. In addition, the consistency of the stimuli produced by the vibration plate
during that initial study was less precise, and therefore the variability of the vibratory
stimuli may have contributed to improvements in muscle strength. These factors should
be considered in future studies investigating the utility of vibration as a therapeutic
modality in DMD, as well as other populations. I would recommend that additional
studies investigating dystrophic mice use a mean frequency of 90 Hz with an acceleration
ranging between 0.6 to 1.0 g and also lower the precision of vibration device such that
the stimulus is more variable. This recommendation is based on evidence indicating that
the anabolic response to vibration is more profound with 90 Hz, rather than 45 Hz, and
the applied stimulus varied as much as 48% [155]. Further investigations should also
consider utilizing the dko mouse model of DMD, which has a more severe musculoskeletal
phenotype compared to mdx mice and better mimics the disease progression seen in
patients with DMD.
Additional therapeutic strategies should also be considered to improve bone health
in DMD. Low intensity vibration is one of many physical treatment modalities aimed
at restoring bone health. It remains possible that other low-intensity physical activities
may better evoke an osteogenic response than that seen with vibration. The use of
dystrophic mice may aid in identifying such modalities. Clinical research should also
consider encouraging patients to continually incorporate physical activity in their daily
lives, and aim to prolong the duration of these activities rather than increase the inten-
sity at which activities are preformed. For example, simple activities such as standing
may preserve bone health, or thwart bone loss, in advanced stages of the disease if
126
performed intermittently throughout the day for short durations.
Preservation of mechanical loading may be the key to preserving bone geometry and
strength in patients with DMD in effort to reduce the incidence of fragility fractures.
In conclusion, my thesis work has identified two mouse models of DMD that may aid in
identifying such therapeutic modalities, and as a result, has contributed to the overall
advancement within the field of bone health in DMD.
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Appendix 1. Summary of the skeletal effects attributed to low intensity, high frequency vibration in rodent models published through 2009. 
Reference Population Age Protocol Duration Acceleration 
(g) 
Frequency 
(Hz) 
Outcome 
C57BL/6 Mice 
Judex, Donahue, 
Rubin, 2002 
(Judex, Donahue et 
al. 2002) 
C57BL/6, 
BALB/cBYJ, 
And 
C3H/HeJ 
16 wk 10 min; 
5 d/wk 
15 d and 
21 d 
0.25 45 C57BL/6 mice had sig greater BFR than other strains. 
 
Metaphysis: 
↑ 69% BFR/TV, ↑ 50% Tb.Th 
Luu, Capilla, 
Rosen, Gilsanze, 
Pessen, Judex, 
Rubin 2009 (Luu, 
Capilla et al. 2009) 
males 7 wk 15 min; 
5 d/wk 
6 wk 0.2 90 Metaphysis:  
↑ 10.4% Tb.N, ↑ 23% Conn.D,  
↓ 11% Tb.Sp 
Garman, Gaudette, 
Donahue, Rubin, 
Judex 2007 
(Garman, Gaudette 
et al. 2007) 
female 19 wk 10 min; 
5 d/wk 
3 wk 0.3  
0.6 
45 0.3g Metaphysis: 
↑ 88% BFR/BS,  
↓ 23% Conn.D 
 
0.6g Metaphysis:  
↑ 66% BFR/BS;  
↓ 25% Conn.D 
 
0.6 Cortical bone of Metaphysis: 
↑ 13% Co.Th, ↑ 10% Co.Area 
Christiansen, Silva 
2006 (Christiansen 
and Silva 2006) 
 7 mo 15min/d; 
7 d/wk 
5wk 0.1 
0.3  
1.0 
45 Metaphysis 0.1:       Metpahysis 1.0: 
↑ 32% BV/TV         ↑ 43% BV/TV 
 
Veretebrae 0.3: 
Tb BV/TV Significantly decreased from 0.1 and 1.0 g 
 
BFR/TV, Bone formation rate per tissue volume; Tb.Th, Trabecular thickness; Tb.N, Trabecular number; Conn.D, Connective density; Tb.Sp, 
Trabecular spacing; BFR/BS, Bone formation rate per bone surface; Co.Th, Cortical Thickness; Co.Area, Cortical area;, BV/TV, Bone volume per 
tissue volume; ↑ Increased; ↓ Decreased; g acceleration measured in units of gravity 
 
 
149 
 
Reference Population Age Protocol Duration Acceleration 
(g) 
Frequency 
(Hz) 
Outcome 
BALB Mice 
Xie, Rubin, Judex 
2008 (Xie, Rubin et 
al. 2008) 
female 8 wk 15 min; 
5 d/wk 
6 wk 0.3 45 Metaphysis: 
↑ 74% Tb MS/BS, ↑ 8% Tb.BV, ↑ 8% Co.A, ↑ 21% 
CSMI, ↑ 12.5% Marrow Area 
Ozcivici, Garman, 
Judex 2007 
(Ozcivici, Garman 
et al. 2007) 
Hindlimb 
Unloaded 
female 
4 mo 20 min; 
5 d/wk 
3 wk 0.6 45 Vibrated limb vs HU limb:  
Vibration ↓ loss of BV/TV, Tb stiffness, Conn.D, and 
Tb.N 
 
Metaphysis vs AC: 
↓ 12% Tb.N, ↓ 22% Tb.Th, ↓6% Conn.D, ↓ 44% Tb 
stiffness, and ↓ 38% 
Xie, Jacobson, 
Choi, Busa, 
Donahue, Miller, 
Rubin, Judex 2006 
(Xie, Jacobson et 
al. 2006) 
Female 
Vibration vs 
Vibration + 
Rest 
Inserted 
Loading 
8 wk 15 min 
165 min; 
5 d/wk 
3 wk 0.3 45 Metaphysis 15 min: 
↑ 30% Co BFR 
Judex, Zhong, 
Squire, Ye, et al. 
2005 (Judex, 
Zhong et al. 2005) 
female 16 wk 10 min; 
5 d/wk 
4 d and 21 
d 
0.3 45 ↑ 55% Tb and Co BFR/BS 
 
Trabecular Bone: 
↑ 32% BFR, ↑18% MS/BS 
 
Tb MS/BS, Trabecular mineralized surface per bone surface; Co.Area, Cortical area; CSMI, Cross-sectional moment of inertia; HU, hindlimb 
unloaded; Tb, Trabeculae; Conn.D, Connective density; Tb.N, Trabecular number; AC Age-matched controls; Tb.Th, Trabecular thickness; Co BFR, 
cortical bone formation rate; BFR, Bone formation rate, ↑ Increased; ↓ Decreased; g acceleration measured in units of gravity 
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Reference Population Age Protocol Duration Acceleration 
(g) 
Frequency 
(Hz) 
Outcome 
Rats 
Rubinacci, , et al. 
2008 (Rubinacci, 
Marenzana et al. 
2008) 
Female 
OVX 
Sprague 
Dawley 
3 mo 20 min; 
5 d/wk 
2 mo 0.6 
 3.0 
30 Diaphysis 3.0g: 
↑ 10% ToA, ↑ 8% CoArea, ↑ 5% periosteal perimeter, ↑ 
7% endosteal perimeter 
Oxlund, Ortoft, 
Andreassen, 
Oxlund 2003 
(Oxlund, Ortoft et 
al. 2003) 
OVX+WBV 12 mo 30 min 90 d 1.16 
3.62 
8.15 
17 
30 
45 
17Hz: ↑ 81% MAR 
30Hz: ↑ 100% MAR 
45Hz: ↑ 84% periosteal BFR, inhibition of Endocortical 
resorption 
Rubin, Xu, Judex 
2001 (Rubin, Xu et 
al. 2001) 
AC 
Vib 
HU 
HU+Vib 
12 wks 30 min; 
5 d/wk 
28 d 0.25 90 Vib vs AC: ↑ 97% BFR/BV, ↑ 76% MS/BS 
HU + Vib vs HU: ↑ ~33% BFR/BV, ↑ 40% MS/BS 
Flieger et al. 1998 
(Flieger, 
Karachalios et al. 
1998) 
Sham 
Sham + Vib 
OVX 
OVX + Vib 
12 wks 30 min; 
5 d/wk 
12 wk 2.0 50 Vib preserved bone mass in OVX mice 
Yang, Jia, Ding, 
Wang, Qian, Shang 
2009 (Yang, Jia et 
al. 2009) 
 
HU 
Vib 
HU+Vib 
4 wks 15 min; 
7 d/wk 
28 d 0.1-1.0 10-60 HU+Vib vs HU: ↑ 10 % femur BMD, ↑ 7% Tibia BMD 
 
Elastic Modulus: ↑ 28% and 43% in Vib and HU+ VIb 
compared to respective control. 
 
Stiffness: ↑23% HU+Vib compared to HU. 
Judex, et al. 2007 
(Judex, Lei et al. 
2007)  
OVX  
OVX + 
45Hz 
OVX +90Hz 
6-8 mo 10 min; 
5 d/wk 
28 d 0.15 45 
90 
Metaphysis 90Hz: 
↑ 159% Tb BFR/BS, ↑ 40% Co BFR/BS (vs 45Hz) 
Epiphysis 90Hz: 
↑ 22% Tb BV, ↑ 11% Tb.Th, ↓ 35% Tb.ConnD 
ToA, Total Area; CoArea, Cortical area; MAR, mineral apposition rate; BFR, Bone formation rate; AC Age-matched controls; BFR/BV, Bone formation rate per 
bone volume; MS/BS, Mineralized surface per bone surface; HU, hindlimb unloaded; OVX, ovariectomized; VIB, vibrated; BFR/BS, Bone formation rate per bone 
surface; Tb BV, Trabecular bone volume; Tb.Th, Trabecular thickness; Conn.D, Connective density; ↑ Increased; ↓ Decreased; g acceleration measured in units 
of gravity 
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